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Abstract
Comprehensive statistical models for non-normally distributed cancerous tumor sizes are
of prime importance in epidemiological studies, whereas a long term forecasting models
can facilitate in reducing complications and uncertainties of medical progress. The statis-
tical forecasting models are critical for a better understanding of the disease and supply
appropriate treatments. In addition such a model can be used for the allocations of budgets,
planning, control and evaluations of ongoing efforts of prevention and early detection of
the diseases.
In the present study, we investigate the effects of age, demography, and race on primary
brain tumor sizes using quantile regression methods to obtain a better understanding of the
malignant brain tumor sizes. The study reveals that the effects of risk factors together with
the probability distributions of the malignant brain tumor sizes, and plays significant role in
understanding the rate of change of tumor sizes. The data that our analysis and modeling is
based on was obtained from Surveillance Epidemiology and End Results (SEER) program
of the United States.
We also analyze the discretely observed brain cancer mortality rates using functional
data analysis models, a novel approach in modeling time series data, to obtain more accu-
rate and relevant forecast of the mortality rates for the US. We relate the cancer registries,
race, age, and gender to age-adjusted brain cancer mortality rates and compare the varia-
tions of these rates during the period of the study that data was collected.
vi
Finally, in the present study we have developed effective statistical model for heteroge-
nous and high dimensional data that forecast the hazard rates with high degree of accuracy,
that will be very helpful to address subject health problems at present and in the future.
vii
Chapter 1
Cancer: A Historical Perspective
1.0.1 Epidemiology of Cancer: Now and Then
It is believed that the scientist started understanding the human body during the Renais-
sance, beginning of 15th century. Understanding blood flow from the heart to the different
parts of the body was a mystery before an autopsy was done by Harvey (1628). In 1761,
Giovanni Morgagni introduced a ground breaking discovery by relating autopsy with pa-
tient’s illness through pathological findings after decease. This was the beginning of sci-
entific study of cancer called oncology (see www.cancer.org). After the development of
the autopsy it took almost two century to develop an anethesia (1859), one of the major
milestone achieved by scientific community, to accelerate the classical cancer surgery such
as radical mastectomy. In the nineteenth century microscopic pathology came into practice
to cure patient’s illness. Credit goes to founder of cellular pathology Rudolf Virchow the
“Father of Modern pathology”, whose work led the scientific community to detect whether
or not the cancer is completely removed after surgery.
In 1713, Bernardino Ramazzini introduced the connection of hormones and sexually
transmitted disease to breast cancer. The description of occupational cancer: chimney
workers, and behavioral cancer: smokers, were coined by Percival Pott in 1775 and John
Hill in 1761 respectively. These three findings are considered to be the founding stones
for the study of epidemiology (a study of causes, distributions and control of the disease).
The fist induction of cancer was made possible at Tokyo University by scientist duo Kat-
susaburo Yamagiwa and Koichi Ichikawa in 1915 by applying coal tar to rabbit skin.
1
After 150 years of the discovery of carcinogen; a pioneering work by the Nobel laure-
ate Peyton Rous in 1911 introduced viral cancer called sarcoma, also called “Rous virus”.
Number of viruses are linked to human cancer today, including but not limited to hepatitis
B or C, human immunodeficiency virus (HIV), and Human papilloma viruses (HPVs). Re-
cent report (April 2013) of World Health Organizations International Agency for Research
on Cancer (IARC) has revealed more than 100 chemical, physical, and biological carcino-
gens for human cancer [1].
By the middle of 20th century, another Nobel laureate duo James Watson and Francis
Crick were able to disclose the exact chemical structure of DNA, the primary material in
genes. The knowledge of DNA and genes revealed new risk factors associated with cancer
including the new DNA sequences by viruses and mutation (genetic damage). Conse-
quently, the discovery of oncogenes (cause cells to grow out of control) and tumor suppres-
sion genes (slow down cell division) in 1970s for overall cancer and the 1990s discovery
of BRACA1 and BRACA2 for breast cancer gave even more closer look to investigate the
risk factors particularly associated with breast cancer (www.cancer.gov).
The continuous investment of time, efforts and investments has shown remarkable progress
in terms of early detection of cancer in late 20th century and early 21st century. During the
1970s, about 1 of 2 people diagnosed with cancer survived at least 5 years. Now, more than
2 of 3 survive that long. The current report of American cancer society shows that there are
more than 11 million cancer survivors in the United States alone (www.cancer.org).
Most importantly, the scientific community seems to have realized that it may be dif-
ficult or most probably impossible to fight against cancer through medical research only.
The whole genre of science and medicine are coming together forming interdisciplinary
research groups convoluting science and medicine together. A case in point is Stand Up
to Cancer (SU2C)[2], a group of people generating finances for funding research teams to
fight against cancer through interdisciplinary collaborations . An interesting article about
the results and progress made by collaboration of diverse group of experts: geneticists,
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pathologists, biostatistics, biochemists, imformaticists, oncologists, surgeons, nurses and
technicians can be found in [2].
All tumors are not cancerous, tumors that are not cancerous are called benign. Benign
tumors are not life threatening in most of the cases but in the case of brain even benign
tumors can be life threatening. In this report, we primarily focus our investigation of the
the distributions of malignant primary tumor sizes and the mortality rates due to malignant
brain tumors.
Researchers who are working to achieve some reasonable progress name cancer as a war,
attacking from all possible directions [3]. Only parameters that can judge the progress in
this war are “mortality rates”. Indeed, the achievements in the war on cancer are about
reducing mortality, saving lives-enjoying more birthdays. In this report we spiral down our
search in the area of brain tumors and related mortality rates. The first part of the disserta-
tion discusses the probability distributions of the brain tumor sizes in different population
subgroups, and in the second part reports the trends in mortality rates and forecast the rates
for different demographic, racial and age groups.
1.1 Brain Tumor
Brain tumors are the second leading cause of death in children (males and females) under
20, second leading cause of cancer related deathes in males ages 20-39 and fifth leading
cause of cancer in females ages 20-39 (see www.abta.org). Secondary (metastases) brain
tumors are the one which are spread to the brain from another part of body. The most likely
cancers that can metastasize are lung, kidney, breast, and skin. Because of the insufficient
information about metastasized cancer we centralize our investigation to primary brain and
central nervous system tumors.
The Surveillance Epidemiology and end Results (SEER) research data base include
SEER incidence and population data associated by age, sex, race, year of diagnosis, and
geographic areas (including SEER registry and county) and sizes of tumors. In Figure1
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we present the schematic diagram to present the number of primary brain and central ner-
vous system tumor sizes recorded during the period of our study [4]. Figure 1 depicts the
demographic, histology, and racial classification of brain and CNS tumor sizes. The clas-
sification of tumor histology is based on RD Barr [5] using ICD-O-3 definitions of cancer
morphology and topography. In chapters 2 and 3 we study the probability distributions of
brain tumor sizes and their demographic and racial variations.
Figure 1.: The Classification scheme of brain tumor. Above classification scheme for brain tumors is based on the classification scheme
proposed by RD Barr and colleagues. The variables were updated from the original ICD-O-2 based classification scheme using ICD-O-3
definitions for cancer morphology and topography.
In the following sections we compile the relevant literature of primary brain and central
4
nervous system (CNS) tumor distributions and the brain cancer mortality rates. In addi-
tion, an attempt is made to table cases to support the relevance of studying distributions of
primary brain tumor sizes and mortality rates.
1.1.1 Skewed Distributions
Probability distributions of samples are the basics to determine inferential statistics from
the parent population. Some of the most frequently used inferential measures in statistics,
p-values and confidence intervals are direct consequence of the underlying probability dis-
tribution of the data under null hypothesis. In chapter 2 we demonstrate the underlying
probability distributions of primary brain and central nervous system tumors in major de-
mographic and racial subgroups of the population under the study period 1973-2006. In
chapter 2 we present a comprehensive review of the brain tumor data and the probability
distributions of the brain tumor sizes. Our work in chapter 2 is a continuation of doctoral
dissertation of Dimitris Vovoras [6]. First couple of diagrams and tables of the descriptive
statistics including Table 1 are also present in [6] and in our joint publication (Pokhrel,
2012) [7].
The statistical significance between differences of tumor sizes together with the highly
skewed nature of brain tumor sizes guided us to model the effects of covariates on tumor
sizes by using a nontraditional method of modeling called “Quantile regression model”
[8, 9].
1.1.2 A Complete Picture of the Data
One of the fundamental tasks of statistics is to bring the diversity of the data into the pic-
ture. It is becoming normal to hear the abnormalities: drought in the rainy seasons, white
Himalayas turning into black rocks, unseasonable flood, low survival rate of young cod in
North Atlantic (see United nations Millennium development goals report, 2009). Statisti-
cally, these types of extreme patterns are not explained by Gaussian distributions. Focusing
too much on average may lead us to lose the effects of extreme values towards both tails of
the distributions. Sir Francis Galton famously defended the “charm of statistics” as
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“.. if the mountains of Switzerland could be thrown into its lake, two nuisances would
be got rid of at once (Natural Inheritance, p.62)”.
The method of least square primarily depends on mean and its deviations from the ob-
served values. Exclusive focus on mean may cause one to ignore the variables at right
and left end of the data, which in most cases also carry the “charm of statistics”. Thus,
a methodology which can reveal the effects of the distribution of data at the higher end
(mountains) and lower end (lakes) can preserve the real beauty of data (nature). Quantiles
are subsets of percentiles; the quantile regression model was introduced by Koenker and
Bassett [8] which can reasonably model the heavy-tailed data[10], like brain tumor sizes.
Advancement in methodology and their multidisciplinary applications further reveal
the usefulness of quantile regression to uncover heteroscedasticity in a regression model
Buchinsky [11]. In quantile regression, we view the complete landscape of statistics by
minimizing a simple asymmetric version of absolute error yielding the estimates of condi-
tional quantiles (see Koenker,2005)[12]. The robust test of heteroscedasticity of quantile
regression is discussed in Gilbert Bassett, computational issues together with a algorithm
presented in Koenker and DOrey [13], and [14]. The idea of Frisch-Newton algorithm in
sparse quantile regression are discussed in (Koenker and Ng 2005) [15]. The computational
issues of quantile regression are addressed, in most part, R package (quantreg) (2009).
A brief review of the applications of quantile regression and its applications in finance
and environmental modeling is discussed in Yu [16] whereas the quantile regression ap-
proach is used to study the effects of innovation for fast-growth firms in Coad and Rao
[10]. A measure of risk called value at risk (VAR) using quantile regression is studied in
Lauridsen [17], a general discussion of return based analysis using quantile regression was
given by Bassett and Chen [18]. Quantile regression is regarded as a complete measure of
variation of inequality and income studies in labor economics (see Buchinsky) [11].
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Quantile regression for time series are demonstrated with examples in Cai [19] and Gan-
noun [20] using kernel density approach. Quantile regression has also been applied for cell
count data ; see (Lipsitz et al. 1997) [21]. Bayesian modeling approach for quantile regres-
sion is discussed in (Yo and Moyeed, 2001) [22], whereas Kottas and Gelfand proposed
mixture model for errors in median regression model. A new adaptive-lasso-based variable
selection procedure for quantile regression with censored outcomes is proposed in (Wu and
Liu 2009)[23].
In chapter 3 we present a comprehensive picture of the distribution of brain tumor sizes
using quantile regression method (Koenker, 2005) [12]. Our investigation is spiraling down
to develop the nucleus of the effects of covariates on brain tumor sizes. The right skewed
probability distributions tumor sizes for different subgroups of the population guided us
to model the data using quantiles of the tumor sizes. The rate of change of tumor sizes is
observed to be different for lower and upper quantiles of the distributions without making
any distributional assumptions of error term in the model.
In chapters 4 and 5 we move one step forward from the quantiles. We further strengthen
our models by treating brain cancer mortality rates as a smooth function of age. For strong
connection between quantile regression and functional data analysis see (Koenker and Port-
noy, 1994) [24], where quantile regression is applied to the spline smoothing problem. It is
ironic that smoothing and interpolation are the building blocks for functional data.
1.2 Functional Paradigm
1.2.1 Overview
Functional data analysis (FDA) was coined by (Ramsay and Dalzell, 1991) [25]. Func-
tional data are a collection of functions, curves, shapes and images. FDA started gaining
momentum in the literature of statistics after the publication of a pioneering book “Func-
tional Data Analysis” (Ramsay and Silverman, 2005) [26]. The idea of presenting data as
a function was put forward by Ramsay in (1982 and 1988) where we can find a strong case
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for new type of multivariate data-now called functional data. The basic idea behind FDA
is to express discrete observations arising from time series in the form of functions. Each
function is considered as a single unit of data such that the statistical techniques from multi-
variate statistics are used to develop models to explore the inherent continuous dynamics of
the data by significantly reducing noise through curve smoothing (Ullah 2013, Ramsay and
Silverman 2005, Hyndman 2007, Eubank1999, Hastie1990) [26–30]. The development of
technology is increasingly favorable for the collection of data with continuum.
The development of technology, medical equipments, and increasing awareness in pub-
lic health are considered to be a major contributor of aging population (IARC, 2012). The
future of social security, health care, insurance is directly influenced by mortality rates.
Lee-Carter model and its extension Lee and Miller (2001) [31] are used as a point of ref-
erence in forecasting mortality rates and life expectancy by the governments of the United
states and United Kingdom (see www.socialsecurity.gov).
In chapters 4 and 5 we develop FDA models based on the advancement of classical
Lee-Carter (LC) time series forecasting model. The LC method is criticized for its lack of
incorporation of the cohort effects, and lower forecasting (Lee Miller, 2000) [31]. We use
generalized LC model proposed by Hyndman and Ullah (2007) in the functional paradigm
(Ramsay and Silverman, 2005) [26], which incorporates more general time series methods
and more sets of components to measure the variability of the data. In addition, state space
methods of exponential smoothing is used for forecasting time series coefficients which re-
sults in more accurate forecasting than original Lee-carter method (Booth et al.,2006) [32].
In chapter 4 we report FDA models of brain cancer mortality rates for demographic
subgroups of the population in the United states from 1969-2008. Forecast of the mortal-
ity rates are presented for different clusters of age groups. We investigate the racial and
regional effects on brain cancer mortality rates in chapter 5. We aim to document the appli-
cations of a new modeling technique “Functional data Analysis” to estimate future trends
mortality rates for different regions, demography, and age.
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The purpose of chapter 2 is to demonstrate the probability distributions of brain tumor
sizes together with the possible demographic and gender effects on heterogenous tumor
sizes through quantile regression model.
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Chapter 2
Parametric Analysis of Malignant Brain Tumor Sizes
2.1 Introduction
The importance of epidemiological, medical data and inference on the extent possible for
primary brain tumors and tumors of the Central Nervous System (CNS) has been previ-
ously recognized [33, 34]. Relevant rates and prognostic information come primarily from
clinical trials and population registry data. Clinical trials usually provide more complete
information on prognostic factors, since one pathology has been reviewed as a whole. On
the other hand, estimates based on population registry data are reflecting a bigger picture
of patients but with considerably larger variance for the times and types of diagnoses.
Many studies for tumors of the brain and CNS have examined and interpreted descrip-
tive and epidemiologic data suggesting possible explanations for the changes in the disease
rates. Brain tumor growth and its differentiations account for some of the variability in the
survival rates emphasizing the importance of tumor size in the prognosis of patients with
brain tumor [35, 36]. The statistics reflected in this study represent a significant portion of
the US population and the data is maintained with high standards for different geographical
and ethnic populations, supporting our central goal to report what may possibly make the
brain and CNS an undesirable environment for tumor progression.
In the present study, we select the size of the malignant tumor to be the variable of in-
terest for different types of tumors and demographic characteristics. we aim to present
our findings with regard to diagnosed malignant brain tumors in the USA from 1973 up to
2006. The National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER)
program provided us with information for malignant brain tumors [37]. The distribution of
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tumor types with age is reported by the Central Brain Tumor Registry of the United States
(CBTRUS) [38]. Higher incidence rates in males than in females for most histologies have
been reported in [39], as well as racial differences in occurrence rates. Trends in incidence
and survival in the United States have been studied in [40], increased risk of brain cancer
was associated with being male, Caucausian, elderly. Prevalence rates for the US popula-
tion are studied in [41]. In [42] and [43] cancer survival trends are evaluated and changes
in the survival rates suggest possible explanations for the improved prognosis.
To better understand the relationship between demographic characteristics and the brain
tumor prognosis we identified the probability distributions that best describe the variability
of the tumor size records for different races and sexes. Such a characterization is essen-
tial in order to obtain information about the central tendency, variance and skewness of
distributions specific to race and sex and postulated about their effect on the tumor size.
Furthermore, in an attempt to better understand the role of age on the tumor size, we study
its effect on the distribution of tumor sizes in the presence of two other predictors, namely
race and gender and considered all possible interactions as potential prognostic factors for
the tumors’ variation.
2.2 Selection and Description of Participants
The discussion below presents the data from several cancer registries in the United States of
America, as well as the complete compilation of various brain tumor types included in the
study. Finally, we tabulate the distribution of tumor types with respect to age groups, race
and gender. The Surveillance, Epidemiology and End Results program is a comprehensive
source of population based information on cancer registries covering 28% of the popula-
tion in the USA collecting complete and accurate data on all cancers diagnosed. SEER
periodically report incidence, mortality and survival data as well as the extend of disease at
diagnosis and link those with other national data sources to identify unusual changes and
differences in the patterns. Specific goals of SEER include the facilitation of collaboration
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among the scientific community and the encouragement in use of surveillance data from
researchers, public health officials, policy makers and the public for cancer prevention,
monitoring and control interventions.
In this study we analyze data on malignant primary brain tumors diagnosed from 1973
through 2006 which are available for the following registries: Atlanta, Connecticut, De-
troit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, and Utah,
Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Tumor Registry,
Greater California, Kentucky, Louisiana, and New Jersey. The data set includes 72,770
primary malignant brain tumor cases: 37,150 males and 35,620 females.
The information for the histology of the brain tumors provided by SEER includes defi-
nitions for cancer morphology and topography and is based in the ICD-0-3 histology [44].
Primary site codes are C000-C809 and ICD-O-3 histology codes are 9161-9571 as well as
8000-8005 finally, 0, 1 and 3 are ICD-O-3 behavior recodes. Tumors vary greatly in size
and positions, the shape is also inevitably subjective and becomes infeasible in large data
sets. SEER records for primary malignant tumors were measured as the largest dimension
or diameter of the tumor in mm’s. The research data we are using in our study includes
11,331 male (87.6% white, 5.8% black, 6.6% other races) and 11,027 female (84.7% white,
7.5% black, 7.8% other races) individuals with recorded tumor sizes.
2.2.1 Technical Information
The classification of tumors for adolescent and young adults (AYA) was developed to bet-
ter understand major cancer sites and facilitate the reporting of cancer incidence rates and
trends. The histological site groups for the tumors that are used in the SEER have been
based on the classification scheme proposed in [5] for cancer morphology and topography;
six main diagnostic groups are defined, half of them have subgroups of two or three mem-
bers. It is mentioned in the paper cited before that “Included in the considerations at that
time were the desirability of having a standard framework while allowing for the flexibility
of subdivisions within a small number of main groups, and the allocation of the maxi-
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mum number of codes to specific categories so that the number of malignancies grouped
as “other” is minimized.
The groups are further delineated for more detailed analysis of the information in terms
of specific histological subgroups. Astrocytoma, is subdivided in specified low grade
astrocytic tumor, glioblastoma and anaplastic astrocytomas, astrocytoma non-otherwise
specified (NOS). Other glioma, ependymoma, medulloblastoma and other primitive neu-
roectodermal tumors (PNET) subdivided in medulloblastoma, supratentorial PNET. Fi-
nally, other specified intracranial and intraspinal neoplasms, unspecified intracranial and
intraspinal neoplasms subdivided in unspecified malignant intracranial and intra spinal neo-
plasm and unspecified benign/boarder intracranial and intraspinal neoplasms, the classifica-
tion scheme was presented in Figure 1. Also, we repot a schematic diagram of the patients
whose information on malignant brain tumor sizes is available in the data during the period
of our study in Figure 2.
Descriptive information for the total number of tumors by race, sex, histology is pre-
sented in Table 1, the numbers shown at the body of the table refer to percentages of the
diagnosed population out of the total numbers found on the right column. Cases are racially
classified as white or nonwhite. The most frequently reported histologies are Glioblastoma
and anaplastic astrocytoma (32.5%), Unspecified malignant intracranial intraspinal neo-
plasms (16.2%) and other specified intracranial and intraspinal neoplasms (13.6%) which
account for over one half of the reported tumors. A large number of astrocytomas (21.8%)
is classified as non-otherwise specified. Age distributions differ by histology type sug-
gesting different etiologic factors are active. Medulloblastic tumors are more prevalent in
children, 69.7% of medulloblastoma patients are diagnosed before the age of 20 and more
common among males [45]. Finally, ependymoma is more frequent in females than males,
for a comprehensive analysis of rates and their time trends see [46].
Considering the importance of studying mean tumor sizes we further delineate the data
by histology and gender. The vast majority of people in the data set were white (87.3%)
whereas diagnosed tumors in blacks comprised 7.1% of the total number of patients. About
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Table 1: Characteristics of the study population by histology type, race, and gender. The numbers shown at the body of the table refer
to percentages of the diagnosed population and the sums of the subgroups listed do not equal the total. Tumor types included in the total
may not be in a specific subgroup of SEER classification.
Age category Race/Gender
Histology 0-19 20-64 65+ White
male
Non-
white
male
White
fe-
male
Total
Astrocytoma
Specified low grade astrocytic
tumor
9.1 43.8 46.9 45.3 6.2 42.3 6558
Glioblastoma and anaplastic
astrocytoma
9.6 47.0 43.3 46.6 5.6 42.9 23661
Astrocytoma NOS 9.8 43.6 46.5 42.8 9.2 37.9 8431
Other Glioma 10.0 43.6 45.8 45.4 7.2 40.8 7856
Ependynoma 5.8 52.1 42.0 30.9 9 43.8 1731
Medulloblastoma and other
Primitive Neuroectodermal
Tumors (PNET)
Medulloblastoma 69.7 26.7 3.4 48.8 3.5 36 86
Supratentorial PNET 6.5 45.2 48.2 50.4 3.2 43.5 1707
Other specified intracranial and
intraspinal neoplasms
9.0 51.7 39.2 37.4 7.9 40.8 9901
Unspecified intracranial and in-
traspinal neoplasms
Unspecified malignant in-
tracranial intraspinal neo-
plasms
11.7 52.3 35.9 50.4 4.2 41.8 11792
Unspecified benign intracranial
intraspinal neoplasm
3.1 58.3 38.5 30.8 4.9 57.5 961
Total 9.3 46.3 43.8 44.8 6.2 42.5 72770
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9.4% of the tumors occurred in children (0-19 years old), whereas 46.3% of them were in
the 20 to 64 age group, with the remaining 43.9% occurring in the elderly (65 years or
older). Thirty six sample means of six histologies for three age groups and sexes along
with the corresponding sample sizes are tabulated in Table 2.
Table 2: Average tumor sizes (in mm) by major histological type for primary brain tumors across three different age groups (0-19,
20-64, > 65 years of age) with corresponding number of diagnosed cases in italics.
Age Groups (Males) Age Groups (Females)
Histology 0-19 20-64 65+ 0-19 20-64 65+
Astrocytoma 43.35(704) 43.36(3328) 42.91(2096) 42.82(517) 39.75(2805) 38.22(2305)
Other
Glioma
42.27(222) 44.37(867) 45.17(562) 46.42(168) 42.67(617) 40.69(605)
Ependymoma 41.35(23) 41.91(257) 41.56(130) 39.56(18) 35.95(326) 28.11(307)
Medullob-
lastoma
43.86(70) 46.13(287) 46.02(159) 40.70(47) 48.72(176) 46.04(141)
Other Speci-
fied
47.33(209) 41.56(1274) 41.00(546) 42.86(188) 35.81(1275) 34.89(878)
Unspecified 42.22(90) 43.01(655) 45.03(510) 36.23(77) 39.58(574) 40.21(561)
For the six histologies combined, the mean tumor size for males is larger than that for
females (p-value < 0.00005). We tested the equality of mean tumor sizes betweeen males
and females for specific histologies; all comparisons were made using the Kruskal-Wallis
test. Only in the case of medulloblastoma we failed to reject the null hypothesis (p-value
= 0.42), the mean tumor size of medulloblastic tumors does not differ. When testing the
same hypothesis for the mean tumor size in the three different racial groups we failed to
reject in all cases. The tabulated average tumor sizes followed by total number of patients
in parentheses, refer to patients diagnosed with malignant brain tumors between 1973 and
2006.
Significantly different mean tumor sizes for histology specific tumors may have impor-
tant implications, but we lack the sufficient information of tumor sizes for different histol-
ogy and racial subgroups. In the following subsections we summarize brain tumor sizes
by, age, race (white, black and other) and gender for patients with different tumor types.
Finally, we report the differences in the probability distributions of the tumor sizes fitted in
population subgroups.
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2.3 Probability Distributions of Malignant Tumor Sizes by Race
and Gender
2.3.1 Descriptive
In Figure 2 we present a subset of the schematic diagram that we presented in Figure 1.
Here we focus our study of brain and CNS tumor sizes on gender and three major races
(white, black and other). The number in each of the boxes represent the available counts
of tumor sizes for respective race and gender. Our analysis in this section is guided by
the following schematic diagram, we attempt to explore the properties of the sizes of tu-
mor by age, race and gender. The geometric behavior of tumor sizes for male and female
tumor sizes presented in Figure 3 is a noteworthy output of the classification scheme of
the following diagram. Age specific average tumor sizes by sex are plotted to present the
Figure 2.: Counts of malignant brain and central nervous system cases for major subgroups of the population by sex and race. Source:
SEER 1973-2006 research data in ASCII Text format
variability for various ages. For specific histologies and age groups we compute the mean
tumor size and statistically compare gender specific averages. Taking into consideration
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the complexity of the data we performed all pairwise comparisons nonparametrically, not
relying in any particular probability distributions. In the subsequent analysis we have dis-
regarded tumors with sizes more than 105 mm, those tumors were deemed to challenge the
robustness of our analysis.
A standardized system for the analysis and presentation of the data regarding tumors
diagnosed in a specific age group for the given classification will greatly facilitate compar-
isons of interest and generate interesting hypotheses. To this end we plot the annual mean
tumor sizes for males and females and comment on the behavior for different data driven
age groups in Figure 3. The different age categories evident here are in accordance with
the scheme that is followed in most of the reports in the literature.
Evidently, average sizes of tumors diagnosed before forty years of age exhibit greater
variability than those tumors diagnosed later and this behavior is common in both sexes.
The data is less volatile for tumor sizes diagnosed in individuals between the ages of forty
and seventy, though the tumor sizes are consistently larger for males.
For the ages less than forty there is a distinction in the behavior between different sexes,
the male records exhibit a concave up behavior with a peak at the age of twenty, while
the female records do not present any clear pattern. Lastly, for the ages above forty male
tumor sizes do not show any clear pattern while female tumors clearly present a downward
trend. We note that tumor sizes for the ages above seventy-five were computed with less
data compared to other ages.
2.3.2 Probabilistic Behavior of Tumor Sizes
For the parametric analysis of the tumor sizes, the probability distributions that best fit the
tumor sizes data are the Dagum or inverse Burr, widely used to describe the distribution
of personal income. The Dagum distribution is closely related to the generalized beta II
probability distribution and can be parameterized either with three or four parameters [47]
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Figure 3.: Average tumor size (the largest dimension or diameter of the primary tumor in mm) against age at diagnosis for tumors
diagnosed from 1973-2006 included in the SEER 9 registries database. Average tumor sizes reported for males are shown with bold
circles and hollow circles are used for female records.
as shown by equation 2.1. Also, the Weibull probability distribution frequently used in
reliability engineering [48], characterizes tumor sizes for females in most of the cases, the
analytical representation is shown by equation 2.3. The probability distributions are se-
lected here using random samples of 5000 from the data at hand; the Kolmogorov Smirnov
goodness of fit test applied to identify best fit the best fit distribution of the subject data [49].
The probability density function (pdf) and the corresponding cumulative distribution
function (CDF) for four parameter the Dagum distribution are respectively given by:
f(x) =
αk
(
x−γ
β
)αk−1
β
(
1 +
(
x−γ
β
)α)k+1 (2.1)
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and
F (x) =
(
1 +
(
x− γ
β
)−α)−k
(2.2)
where, k, α, β > 0 and γ < x <∞.
Similarly, the pdf and CDF of two parameter Weibull distribution are given by the fol-
lowing equations respectively:
g(x) =
(
α
β
)(
x
β
)α−1
exp
(
−
(
x
β
)α)
, (2.3)
and
G(x) = 1− exp
(
−
(
x
β
)α)
, (2.4)
where, α, β > 0 and γ < x <∞.
In the case of the Dagum four parameter distribution αandk are shape parameters, β is
the scale parameter and γ the location parameter. When γ = 0 resulting in the (0,∞)
domain for the probability distribution we refer to the three parameters Dagum distribu-
tion. For the Weibull distribution α, β are the shape and scale parameters, respectively.
The product αk for the parameters of the Dagum distribution measures the rate of increase
from zero for x → 0, or the probability mass of the tail and is larger in the male than the
female, resulting in a greater probability mass in the case of females for the left tail [47].
We list the approximate maximum likelihood estimates of the identified distributional pa-
rameters in Table 3.
Table 3: The identified probability distributions along with the estimates for the corresponding parameters that best fit the malignant
tumor sizes data.
Males Females
All races Dagum (4p):kˆ = 0.36, αˆ = 5.45, βˆ = 55.78, γˆ = 0.06 Weibull: αˆ = 2.02, βˆ = 43.51
White Dagum (4p): kˆ = 0.35, αˆ = 5.65, βˆ = 56.45, γˆ = 0.10 Weibull: αˆ = 2.09, βˆ = 43.98
Black Dagum (4p): kˆ = 0.45, αˆ = 4.31, βˆ = 54.54 Dagum: (4p):kˆ = 0.47, αˆ = 3.68, βˆ =
45.43, γˆ = 0.41
Other Dagum (4p):kˆ = 0.36, αˆ = 5.17, βˆ = 57.57, γˆ = 0.37 Weibull: αˆ = 1.89, βˆ = 44.13
The main advantage of parametric methodology is that the information contained in the
very large data sets can be concentrated in a small number of parameters.
Furthermore, useful information can be drawn directly from the estimated parameters
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for different subpopulation, provided that the differences in the estimated parameters have
a clear biological interpretation. Therefore, one of the undisputed properties required for
the probabilistic models of distributions of tumor sizes is their biological interpretation. To
formulate the analysis we have partitioned the data with regard to race into whites, blacks
and a third class containing the remaining races as well as gender of the patient.
In Figure 4, we plot below the identified probability density curves that best characterize
the tumor sizes for six racial/gender subpopulation. The basic characteristics of the tumor
sizes for those subgroups are reported in Table 4, we can initially note a clear distinction
between the distributions of male and female tumor sizes, the modes of the respective
distributions of tumor sizes are around 40mm and 27mm. In further detail, the probability
distribution for the black females is more skewed compared to any other of the identified
distributions.
The left triad of curves corresponds to PDF’s for the females and the right triad of curves
corresponds to males. The identified probability distributions along with the estimates for
the corresponding parameters that best fit the tumor sizes data are shown below.
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Figure 4.: Plots of fitted probability density functions (PDF) of tumor sizes classified for gender and race. The first three graphs from
the left represent tumor sizes for females and the three graphs on the right are for the density of tumor sizes for the males.
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Figure 5, depicts the cumulative distribution functions for brain and CNS tumor sizes
for males and females. Left most triad is the CDF for tumor sizes of white black and other
races whereas the right triad is for males. The cumulative distribution function is a com-
plete explanation of the random variable. This is particularly helpful to determine to find
the probability of the quantiles of the random variables, confidence intervals, failure rate
functions, reliability functions, and other descriptive statistics. For example, from Figure 5
we can easily find that 20% of the female tumor size for other races are less than or equal to
20 mm, whereas only 13% of the male tumor sizes are of other males race are below 20mm.
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Figure 5.: Plots of fitted cumulative distribution functions (CDF) of tumor sizes classified according to gender and race. The first three
graphs from the left represent tumor sizes for females and the three graphs on the right are for the density of tumor sizes for the males.
Having knowledge of the probability distributions we can have a better understanding of
the tumor sizes variability and estimate basic measures for the tumor records in different
population subgroups. In Table 4 we have listed the means, medians, variances, skewnesses
measure of symmetry, and kurtoses, measure of flatness. We are using the estimated val-
ues of the appropriate distributional parameters to compare the basic characteristics of the
tumor sizes for the populations of interest.
From Table 4, the difference between the mean and median in the black populations is
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about double the corresponding difference in the other populations. Also, skewness for
both the black male and black female populations is larger than other subgroups, that is, on
average there is a higher number of tumor sizes more distant from the median. Although
as we have already mentioned, the black comprise only 7.8% of the individuals in the data
set, there is strong evidence that the variance is largest in the black subpopulation.
Table 4: Estimates of central tendency and variability for tumor sizes classified according to race and gender were obtained using
estimated parameters for the identified probability distributions shown under Figure 3.
Median /Mean Variance Skewness Kurtosis
male female male female male female Male female
Total 40.38/42.36 36.29/38.55 457.10 398.68 1.35 0.62 11.30 0.02
White 40.93/42.65 36.90/38.95 442.18 383.06 1.22 0.58 9.75 0.01
Black 40.35/44.22 33.06/37.84 692.22 707.71 2.69 4.87 68.67 -92.03
Other 41.27/43.62 36.35/39.17 533.25 464.14 1.54 0.71 14.15 0.04
Measuring the size of kurtosis observed in the data sets, we find out that the value for the
black male individuals is three times as big as the second largest. Higher kurtosis means
more of the variance is a result of infrequent extreme deviations from the mean as opposed
to frequent modestly sized deviations. It is worth noting that, on the other extreme, tumor
sizes for black females contain the least amount of extreme observations from the mean
compared to all other data sets.
To our knowledge there has been no systematic analysis of the brain tumor sizes and dif-
ferences associated with the effect of the race and gender on the respective probability
distributions. Such measurements though are commonly used in the evaluation of diag-
nosed tumors and have implications for patient prognosis and treatment [50]. In Table 5
we report probabilities of different tumor sizes for male and female patients based on the
parameter estimates of the fitted probability distributions. The 5-year relative survival rates
related to the tumor size characterization can be found on the last two columns.
Table 5: Cancer of the brain and other CNS: Sex specific probabilities and relative survival rates for different tumor sizes.
Probability Relative survival rate
5-year (%)
Tumor
size
Male Female Brain Other CNS
< 20 mm 0.133 0.18 31.5 89.2
20-50 mm 0.555 0.546 19.8 71.2
> 50 mm 0.311 0.266 20.8 58.3
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It is reported in [51] that for diagnosed brain tumor sizes≤ 20mm, 20−50mm,> 50mm
the 5-year relative survival rates are 31.5, 19.8, 20.8, respectively and 89.2, 71.2, 58.3, re-
spectively for tumors of the other central nervous system. The 5-year relative survival rates
are not significantly different for patients with tumor sizes between 20-50 mm and bigger
than 50mm. Survival differences in subpopulation can be associated to the differences in
the distributions of tumor sizes. A note on joint point survival of brain tumor patients can
be found in (Vovoras, 2011) [50]. In the following section we will attempt to model the
effect of those covariates on the quantiles of the distribution of tumor sizes.
2.4 Contributions
We have developed parametric analysis by defining the probability distribution functions
of primary brain and central nervous system in malignant tumor sizes in the United States,
1969-2006, from which we can obtain the following useful information.
• The probability distribution functions of brain malignant tumor sizes for different sub-
groups of the population which is the cornerstones for the development of statistical
inference on the subject matter.
• The probability distributions that best characterizes the distribution of brain and CNS
tumor sizes for males and females are found to be Dagum and Weibull pdf respectively,
from which we can obtain useful information, such as the expected size of the tumors,
confidence limits of the size of the tumor, etc.
• The graphical representation of probability density functions and the respective cumu-
lative distribution functions could be efficacious tool to facilitate the physicians during
the treatment procedure.
• The findings in the present chapter are essential to the relevant results obtained in Chap-
ter 3.
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Chapter 3
Quantile Regression Model for Brain Tumor Sizes
3.1 Introduction
Our objective in this chapter is to describe explicitly about the effects of gender, race and
age on brain tumor sizes. The average tumor size and its deviation from the data is merely
a satisfactory explanation of the behavior of tumor sizes. In chapter two we found the
probability distributions that best fits the distributions of tumor sizes are highly skewed
“Dagum” and “Weibull”. The standard least square estimate provide an average effects
of covariates on the average “tumor size” and these are not particularly influential in the
present study of tumor sizes. The present study is particularly motivated by an oft-cited
passage of Mosteller and Tukey (1977) :
“ What the regression curve does is give grand summary for the average of the distri-
butions corresponding to the set of x’s. We could go further and compute several different
regression curves corresponding to the various percentage points of the distributions and
thus get a more complete picture of the set. Ordinarily this is not done, and so regression
often gives a rather incomplete picture. Just as the mean gives an incomplete picture of a
single distribution, so regression curve gives a corresponding incomplete picture for a set
of distributions.”
Quantile regression models are primarily useful where extremes of the distributions of
the response variable are important, such as body mass index (BMI) studies; where upper
and lower quantiles of the BMI are critical from public health prospectives. The quantile
regression also exhibits a comprehensive picture if both upper and lower quantiles of the
distributions of response are the primary interests of the present study. The advantage of
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quantile regression over ordinary regression is its flexibility in modeling the heteroscedastic
error distribution (Koenker and Hallock 2001) [9] of the given data. This type of data occur
in many fields including environmental sciences, econometrics, survival analysis, public
health, and many more. Thus, in the present study we proceed to develop statistical models
that adheres different approach by incorporating the extreme values of the subject data and
produce useful results.
3.2 Brain Tumor Sizes and Quantile Regression Model
3.2.1 Quantiles and Optimization
The generalization of univariate quantile to a conditional quantile given one or more co-
variates can be effectively modeled by using quantile regression. Let Y be a real valued
random variable. The cumulative probability distribution function of Y can be written as:
F (y) = P (Y ≤ y). (3.1)
The τ th quantile of Y is defined as the inverse function (Koenker 2005), [12],
F−1(τ) = Q(τ) = inf{y : F (y) ≥ τ} (3.2)
where 0 < τ < 1. More Specifically, median is Q(1
2
).
The idea of quuantiles arise from an optimization problem (Ferguson 1967 p.51 ), and
(Fox and Rubin 1964) [52]. Fox and Rubin studied quantile estimators under the piece-
wise linear loss function. They also verified that the τ th quantile can be found by ordering
the sample observations, as a solution to simple optimization problem (Koenker 2005) [12].
For random sample {y1, · · · , yn} of Y , minimum value of the following sum of the ab-
solute value deviations is attained at sample median
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min
n∑
i=1
|(yi − ξ)| forξ ∈ R.
Similarly, τ th sample quantile ξ(τ), i.e. Q(τ), may be calculated as a solution of the
optimization problem
min
n∑
i=1
ρτ (yi − ξ), forξ ∈ R (3.3)
where ρτ (v) = v(τ − I(v < 0)), 0 < τ < 1. Here I(.) denotes the indicator function.
The sum of squares of residuals are minimized by the sample mean as:
µˆ = min(yi − µ)2 for µ ∈ R. (3.4)
Equation (3.4) can be extended to conditional expectation of Y givenX asE(Y |X = x) =
xTβ by solving
βˆ = min(yi − xTβ)2 for µ ∈ R. (3.5)
Similarly, the linear conditional quantile function, Q(τ |X = x) = xTβ(τ), can be
estimated by solving
βˆ = min ρτ (yi − xTβ) for µ ∈ R. (3.6)
where τ ∈ (0, 1) and ˆβ(τ) is called τ th regression quantile. For example, τ = 1
2
refers to
the median regression which minimizes the sum of the absolute residuals.
3.2.2 Regression Quantile Estimates
Let X = (x1 · · · , xn) be a random variable, and let y = (y1, · · · , yn) be n observed re-
sponses. The linear model for quantile regression is given by
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y = XTβτ + τ (3.7)
where β = (β1, · · · , βp)Tp×1 represents a vector of parameters and  = (1, · · · , n)Tn×1
represents a vector of unknown errors. The τ th regression quantile can be reformulated as
a solution of
min
β∈R
 ∑
{yi≥xTi β}
τ
∣∣yi − xTi β∣∣+ ∑
{yi<xTi β}
(1− τ) ∣∣yi − xTi β∣∣
 . (3.8)
A special case of (3.8), when τ = 1
2
, is called median regression.
One of the earliest reference that we have found in the literature to obtain estimates of
the coefficients of the median regression is through Linear Programming Problem (LPP)
which is called the simplex algorithm (Barrodale and Roberts 1973) [53]. An interior point
approach (Karmakar 1984)[54] is extensively used to solve median regression in which
the interior of constraints is approximated by an ellipsoid. To find the quantile regression
coefficients we have used smoothing algorithm (Madsen and Nelsen 1993) [55], interior
point and simplex method. This smoothing algorithm approximates the objective function
so that Newton-Rapson algorithm can be used to find the coefficients with finite number of
loops.
To be able to measure the effects of population characteristics on the tumor sizes we
proceed to develop regression models for different quantiles of the distributions of tumor
sizes. We begin this section with a brief introduction to the proposed model, and then im-
mediately apply it to our data set. Standard least squares regression models calculate the
average effect of the independent variables on the tumor sizes. However, the focus on the
average tumor size may hide important elements of the underlying relationships. There is
an extensive literature for modeling skewed data using quantile regression. The applica-
tions of quantile regression in economics, microeconomics and econometrics [11, 56] are
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notable publications, several other areas including wealth inequality, food expenditures,
school quality issues and demand analysis are also studied to investigate comprehensive
pictures of the effects of the predictors on the response variable. However, such a method-
ology has not been applied to the subject area of study.
The quantile regression model is preferable in comparison to the usual regression be-
cause of the following major reasons:
• Standard least-squares assumption of normally distributed errors does not hold for our
data base because tumor sizes follow Dagum and Weibull probability distributions.
• Quantile regression models are robust to the heavy tailed probability distributions.
• Quantile regression coefficients βˆτ invariant to outliers of dependent variable (Buchin-
sky,1994) [57].
• Quantile regression models are able to describe the entire conditional probability dis-
tribution of the dependent variable (Alex Coad and Rekha Rao) [10].
Quantile regression models the relation between a set of predictor variables and specific
percentiles (or quantiles) of the response variable by specifying changes in the quantiles of
the response. For example, a median regression of tumor size diagnosed on brain tumor
patients specifies the changes in the median tumor size as a function of the predictors. Also,
the effect of age on 1oth quantile brain tumor sizes of male can be compared with the effect
of age on 10th quantiles of female tumor sizes, this information provides a more complete
picture of gender effect of age and gender on lower or upper end of the distributions of tu-
mor sizes. In addition, in linear regression the regression coefficient represents the change
in the response variables produced by a one unit change in the predictor variable associated
with that coefficient. The quantile regression parameter estimates the change in a specified
quantile of the response variable produced by a one unit change in the predictor variable.
This allows comparing how some percentiles of the tumor size may be more affected by
certain characteristics than other percentiles.
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At various quantiles of the conditional probability distribution of the tumor sizes we
are calculating the coefficient estimates for the regression model as shown in the equation
below:
Qτ = α + β2Sex+ β3Age+ β4Age ∗ Sex+ β5Age ∗Race+ β6Sex ∗Race+  (3.9)
by avoiding the restrictive assumption that the error terms are identically distributed
at all the points of the conditional distribution. We consider races (other, white, black),
gender (female and male ) and age of the individuals as a contributing variables and quantile
of the tumor sizes as dependent variables. Our statistical analysis includes tumor sizes
measured in mm for 22,140 individuals that will be discussed in the results Section. Figure
6, represents a summary of quantile regression results for the subject data. In each plot, the
regression coefficients for 19 different quantiles indicate the effect on the size of the tumor
with a unit change in that variable, assuming that the other variables are fixed, with 95%
confidence interval bands. For example, in the first panel of the picture, the intercept can be
interpreted as the estimated conditional quantile function of the tumor size distribution of
a female infant whose race is “other”. In more detail, the following equation provides the
estimated coefficients for the median of the distribution of the tumor sizes for black males
with age 40.
Q0.5 = 40.208− 1.689− 0.208− 0.069 ∗ 40 + 0.069 ∗ 40− 0.037 ∗ 40 + 3.801 (3.10)
The estimated coefficients for the quantiles of the tumor sizes for the whites which are
plotted in the top right graph show a negative effect on the tumor growth compared to
“other race”. Regarding the effect in the median and the higher quantiles we did not see
any difference with the coefficient in the linear regression case. In the bottom left graph
the estimates of the quantiles regression for the blacks are not significantly different from
zero, even though the effect on the 90th quantile is about 14 times bigger than that on the
average tumor size. In the last graph, in accordance to our OLS findings male tumor sizes
are larger than females, the largest difference between the quantiles for males and females
is 9.93 mm at the 95% quantile (95% CI is between 3.39 and 16.47).
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Figure 6.: A summary of quantile regression estimates for the tumor sizes model involving three covariates and their interaction. For
each of the coefficients we plot the 19 distinct quantile regression estimates. The shaded blue area depicts a 95% point wise confidence
band for the quantile regression estimates, where (race1: white, race2: black, sex1:male).
In Table 6 selected results from the analysis of 10th, 25th, 50th, 75th, and 90th quan-
tiles including coefficients for interaction terms between race, gender and age are tabulated
to identify statistical significance with respect to the quantiles of distribution of the tumor
sizes, while the complete tabulation of the coefficients along with information on the sta-
tistical significance can be found on Appendix A. Age and its interaction with race appears
to a statistically significant factor that affects the change in tumor size. Estimated param-
eter values for the variable age provide evidence that the marginal change is considerably
different between mean lower and upper quantiles of tumor sizes. Specifically, estimated
coefficients predict that the changes in the 5th, 10th, 15th, 20th, 25th, 30th,35th quantiles
of the distribution of tumor sizes are -0.06, -0.09, 0.09, -0.10, -0.12, -0.08 and -0.09 respec-
tively for each additional year of age when the variables race and sex remain fixed were
statistically significant at the 95% level. The effect of age on the conditional distribution of
tumor sizes was not significant for the higher quantiles, the ordinary least squares calcula-
tion show a marginal decrease of 0.05 for each additional year.
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Table 6: Ordinary and Quantile regression estimates of the equation (3.9): the coefficients on ’tumor sizes’ reported for the 10%, 25%,
50%, 75% and 90% quantiles and the mean. Coefficients significant at the 5% level appear in bold.
OLS Quantile Regression
10 25 50 75 90
Intercept 41.027 17.687 28.5 40.208 50.000 68.000
Race 1 0.013 -1.801 -1.258 0.347 0.000 -1.615
Race 2 -0.545 -1.758 -1.3510 -1.689 0.746 -7.014
Sex 1 1.356 2.475 1.816 -0.208 5.000 0.768
Age -0.0544 -0.086 -0.125 -0.069 0.000 0.000
Age*Sex 1 0.054 0.032 0.081 0.069 0.000 0.019
Age*Race 1 -0.003 0.054 0.045 0.000 0.000 -0.076
Age*Race 2 -0.050 0.023 -0.005 -0.037 0.000 -0.019
Sex1*Race1 -0.447 -0.361 0.942 -0.347 -2.000 2.905
Sex1*Race2 2.369 -0.235 1.035 3.801 -0.328 8.246
With regard to the interaction between age and race, for the 5th,15th,20th quantiles of
the distribution of the tumor sizes of the white race the effect is positive and proportional to
the coefficients for a marginal change in the age while this reverses for the higher quantiles
as shown in the table in the Appendix B. We also identified significant interaction between
gender and age for the lower and middle quantles, the control variable being female as
shown in Table 6, uniform across the quantiles and approximately equal to the estimated
effect of the ordinary regression case.
Several of the covariates are of substantial public health and policy interest, the interpre-
tation of their causal effects may be controversial, especially in the case of the gender and
race covariates. In almost all the panels of Figure 6, with the exception of the coefficients
for whites for the 85th quantile, the quantile regression estimates do not lie at any point
outside the confidence interval for the ordinary least squares regression, formal hypothesis
testing is discussed in [58], suggesting that the effects of these covariates may be constant
across the conditional distribution of the independent variable.
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3.3 Discussion
Tumor size is known to be of great prognostic importance, independent of other prognostic
variables, the purpose of this research is to conjecture on the importance of race, sex and age
covariates on brain tumor size. Efforts were made to link tumor size data from registries to
demographic patient information to help researchers postulate histology specific etiologic
risk factors. We have applied probability and regression models to explore their impact on
the sizes of a brain tumor. The vast majority of patients in the data set were white, the
average tumor sizes diagnosed between twenty and forty years of age exhibited the largest
variability, this behavior was common in both sexes. The probability distributions fitted for
the tumor sizes of both male and female patients were strongly skewed, for the black female
population subgroup the least amount of the variance was a result of infrequent extreme
deviations from the mean. Finally, age distributions differ by histology type suggesting
different etiologic factors are active for different histological types.
In addition, we explored the sources of heterogeneity in the brain tumor sizes using quan-
tile regression to identify the effect of homogenous subpopulation associated with disease
progression. The lower quantiles of the distribution of white tumor sizes are lower com-
pared with the “other” race, whereas the 80th and 90th quantiles are significantly higher.
When we compared the tumor sizes of blacks with other race, the estimates of the coeffi-
cients for the distribution of tumor sizes for blacks showed that the higher the quantile of
the distribution of tumor sizes the bigger the difference with the relative quantile for the
other races distribution (Pokhrel, 2012) [59, 60]. The estimated coefficients for age predict
that the effect of age in the lower quantiles of the tumor size distribution is negative when
the variables race and sex remain fixed.
Using the brain tumor registry data provided by SEER we demonstrated differences in tu-
mor sizes for a histology classification. In addition, we estimated the basic characteristics
of the distribution of tumor sizes as well as the significant demographical effects on them.
While several approaches have been considered in the literature, we found inference with
brain tumor sizes a lucid way to discuss the effect of several prognostic factors.
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3.4 Contributions
In this chapter we have developed quantile regression models for the distributional behavior
of malignant brain tumor sizes for different demographic and age subgroups of the given
population. The result of the that the present study will help us accelerate the understanding
the body of knowledge in the behavior of brain tumor sizes.
• Our work is a detailed evaluation of brain tumor sizes with respect to gender, age and
race, that will be helpful to medical scientists, strategic planning, etc.
• We studied potential difference between brain tumor sizes among males and females
and found a significant difference between the gender, such information is important to
medical doctors to address the procedural and clinical strategies for their patients.
• The rate of change of tumor sizes is different for the lower and upper quantiles. This
explored and modeled the heterogeneity distribution of brain tumor sizes, this can be
helpful to find the accurate rate of change of tumor sizes.
• Our findings also revealed that age is a significantly contributing factor for the brain
and CNS tumor sizes, and in some cases we also observed a significant interaction of
age and sex.
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Chapter 4
Forecasting Age Specific Brain Cancer Mortality using Functional
Data Analysis Models
4.1 Introduction
Functional data analysis is about the analysis of information on curves or functions (Ram-
say, 2005) [26]. Functional data is multivariate data with an ordering on the dimensions
(Muller, 2006). In the present study we are interested in the distribution of functions means,
covariances, and relationships of functions to certain responses and other functions. One
of the major advantages of functional data analysis is a strong possibility of using rate
of change or derivatives of curves. In this study we combine methodologies from func-
tional data analysis, nonparametric statistics and time series forecasting. There has been
an intense research in this area during the last decade (Ullah, 2013) [27]. In addition, fu-
ture mortality rates are of great interests of strategic planning and the insurance industry.
Accurate forecasting can be a strong indicator for allocating budget, planning, and policy
making. Here, we develop a forecasting model for crude mortality rates of malignant pri-
mary brain and central nervous system cancer of the United States for the study period of
1969-2008.
The age-specific mortality rates can play a significant role for the allocation of resources
for brain tumor control and evaluations. Primary purpose of this study is to apply func-
tional data analysis techniques to model age-specific brain cancer mortality time trends and
forecast entire age-specific mortality function using state space-approach [28]. Our aim in
the present study is to answers following questions:
i) To capture the subtle pattern of variation in mortality.
ii) To find the prediction interval of the forecast.
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iii) To find a robust model for outlying years.
and
iv) To find a flexible model so that it can incorporate the covariates such as screening and
treatment effects into the analysis.
Currently, most of the forecasting models are based on age-period-cohort methods. These
methods are structured to estimate the mortality rates of breast cancer [61], prostate cancer
[62] and cervical cancer [63, 64]. These methods are basically regression models with mor-
tality or incidence rates as outcome variables using Poisson error distribution with log link
function. The most common problem in these models is non-identifiability of parameters,
very strong parametric assumptions, and sensitivity of projections and lack of inclusion of
most recent changes in cohort effects.
The linear extrapolation and non-linear Poisson distribution models are discussed in
[65, 66] whereas a Bayesian age-period-cohort model with autoregressive smoothing of
each of age, period and cohort components are studied such that the resulting projections
are estimated from current and past trends of the data in [61]. Lee and Carter (LC) [67]
method is one of the most influential methods in demographic forecasting. This is perhaps
the most cited paper by demographic researchers. LC proposed a long term forecasting
method to extrapolate mortality rates and applied it to forecast US mortality rates for the
year 2065.
There has been numerous extensions of LC method, some of the extensions and modifi-
cations of LC method can be found in (Lee and Miller, 2000) [31]; Renshaw and Haberman
(2003)[68], and the applications of LC method in fertility forecasting can found in Lee [69].
The method proposed by Lee and Carter in 1992 has become the leading statistical model of
mortality/forecasting in the demographic literature [70], (Deaton and Paxson, 2004) [71].
It was used as a benchmark for recent Census Bureau population forecasts (Hollmann,
Mulder and Kallan, 2000) [72], and two U.S. social security technical advisory panels rec-
ommended its use, or the use of a method consistent with it (Lee and Miller, 2001)[31].
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A comprehensive discussion of the patterns of mortality rates for then G 7 countries is
presented by Tuljapurkar et. al.[70] using LC method. The LC model predicted 1 to 4 year
higher life expectancy than official projections in the industrial nations, with larger differ-
ences for Japan.
There are numerous uncertainties which affects the mortality rates, however a probabilis-
tically sound forecasting method, like LC method, is particulary useful to address the long
term funding problems of public pension and insurance for increasingly ageing population
in the industrial world.
4.2 The Forecasting Models
4.2.1 Lee Carter Approach: An Overview
The Lee Carter model for Age-Specific mortality rates is given by:
ln(mx,t) = ax + bxkt + x,t (4.1)
where ax is general age shape of age-specific mortality rates, bx represents the tendency
of mortality at age x, and kt is the time varying index. Equation (4.1) is a linear model
of an unobserved period-specific intensity index, with parameter depending on age (LC
1992). LC model uses singular value decomposition (SVD) method for exact least square
fit, however, a simple linear regression method can also approximate the parameters. LC
incorporates a random walk with drift for the time series formed by kt, which is expressed
as:
kt = kt−1 + c+ et (4.2)
where c is the drift term, k is forecast to decline linearly with increment of c, and et are
permanently incorporated in the trajectory (Lee 2000) [31]. The standard error of c could
be used for the detailed measure of uncertainty in forecasting k.
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LC model has created a wave of discussions and applications in demographic forecast-
ing. It possesses numerous attractive features. The simplicity of the model is probably the
most appealing one. The model is probabilistic in nature and provides prediction interval
for future trend of the mortality rates. It is also observed that the historic trend of mortality
is found to be linear, thus the use of random walk with drift found to have good fit [31].
However, the LC model fails to capture the subtle pattern of change, like the influenza of
1918, and Hurricane Katrina of 2005 in the United States where the death rates were signif-
icantly higher than the historical trend of mortality. One concern is that if each age-specific
rate is allowed to change at its own individual rate, the projected age profile of mortality
may depart from plausible, historically observed patterns.
The instantaneous rate of change of mortality can be written as
dln(mx,t)
dt
= bx
dkt
dt
,
where kt is predicted to decrease linearly with constant rate. This implies that age-
specific mortality rates will decrease with a constant exponential rate as mentioned in (LC
1992 P. 665). One of the most penetrating comment about LC method is by Robert Mc-
Nown:
“It becomes clear that forecast of mortality identical to Lee and Carter’s will be pro-
duced by directly projecting each age-specific mortality rate at its historical rate of expo-
nential decline”.
In the following section we discuss about the use of more flexible (Hyndman-Ullah,2007)
[28] method to model the brain Cancer mortality rates which uses multiple functions to
capture the changes in rates.
4.2.2 Why Functional Data Analysis (FDA)?
Our primary goal is to find a robust forecasting model for mortality rates of brain and
central nervous system tumor in the United States. The proposed forecasting model is de-
veloped in the realm of functional data (Ramsay and Silverman 2005) [26] for modeling
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log mortality rates. To develop the functional data, we invoke the nonparametric smooth-
ing techniques to mitigate the existing randomness in the observed data. In addition, the
problems related to age groups and issues of outlying years are reasonably addressed by
using robust principal component analysis (Hyndman and Ullah 2007) [28]. The observed
data is smoothed and principal component analysis is applied after smoothing the observed
data. Hyndman and Ullah’s method of robust principal components decomposition is much
more computationally efficient (see Croux’s contribution to the discussion of Locantore et
al.,1999).
The robust forecasting methodology is a generalization of Lee and Carter method. This
approach uses functional data analysis techniques and treats the age-specific mortality
curves as the units of analysis rather than the discrete observations (Hyndman-Ullah 2007)
[28]. Generalized Lee-Carter method models the mortality rates as a continuous function of
age and captures the subtle variation between years . In addition the smoothness of the data
reduces the observational error and forecast the entire function with prediction intervals
[28].
4.2.3 FDA Model
Let mt(x) denote the mortality rate for mid point of age group x and year t, t = 1, ........n.
We model the log mortality,
yt(t) = log[mt(x)],
and assume that there are an underlying functions ft(x) that we are observing with error
(Erbas et al.) [73]. The mortality rates as a smooth function of age can be expressed as,
yt(xi) = ft(xi) + σt(xi)εt,i , (4.3)
where xi is the center of age-group i (i = 1, .......p), εt ,i is an independent and identically
distributed standard normal random variable and σt(xi) allows the amount of noise to vary
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with the age x. After developing functions of the given mortality rates, we fit the model
ft(x) = µ(x) +
K∑
k=1
βt,kφk(x) + et(x) , (4.4)
where µ(x) is the mean log mortality rate across years, φk(x) is a set of orthogonal basis
functions, and et(x) is the model error which is assumed to be serially uncorrelated [73].
The mean log mortality rates µ(x) are estimated by using penalized regression splines
(Wood, 2000) [74]. The pairs (βt,k, φk(x) for k = 1, 2 · · ·K) are estimated by decom-
posing the data into principal components, where as et(x) is the difference between spline
curve and fitted curve from the model. We wish to estimate the optimal set of K orthogonal
basis functions. Specifically, for a given K, we want to find the basis functions {φk(x)}
which minimizes the mean integrated squared error:
MISE =
1
n
n∑
t=1
∫
e2t (x)dx . (4.5)
This is achieved using functional principal components (FPC) decomposition, [75], applied
to the curves {ft(x)} which provides the least number of basis functions, and explore the
coefficients which are uncorrelated with each other.
4.2.4 Forecasting
Equations (4.3) and (4.4) together yields:
yt(xi) = ln [mx,t] = µ(x) +
K∑
k=1
βt,kφk(x) + et(x) + σt(xi)εt,i. (4.6)
Let βˆ(n, k, h) denotes the h-step forecast of βn+h,k and let fˆn,h(x) denote the h-step ahead
forecast of fn+h(x). Then,
fˆn,h(x) = µˆ(x) +
K∑
k=1
βˆ(n, k, h)φˆk(x) . (4.7)
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To forecast the coefficients from equation (4.7) we use state-space model for exponential
smoothing. Forecast from exponential smoothing methods are estimated recursively where
recent observations are given more weight than historical data. The methods accommodate
additive and multiplicative trend with automatic model selection for the given time series
[73]. The sum of the variances of all individual terms is the forecast variance [28];
V ar
[
yˆn+h,k(x)
]
= σˆ2µ(x) +
K∑
k=1
un+h,kφˆ
2
k(x) + ν(x) + σ
2
t (x), (4.8)
where σˆ2µ(x) is the variance obtained using the smoothing method. The forecast variance
is given by;
un+h,k = V ar
(
βn+h,k|β1,k··· ,βn,k
)
,
νk(x): sum of square of residuals,
σ2µ(x): variance of the smooth estimate µˆ(x),
σ2(x) is estimated by assuming binomial distribution of mt(x), and
ν(x)is the mean of eˆ2t (x) for each x.
We evaluate the accuracy of the mortality forecast by computing the mean integrated
squared forecasting error (MISFE) defined as
MISFE(h) =
1
n−m+ 1
n∑
t=m
∫ [
yt+h(x)− fˆt,h(x)
]2
dx , (4.9)
where m is the minimum number of observations used in fitting the model.
4.3 Brain and Central Nervous System Tumor: Mortality Data
An estimated 69,720 (10% increment from 2010) new cases of primary non-malignant
and malignant brain and central nervous system tumors are expected to be diagnosed in the
United States in 2013 [38]. This caused 13,700 (5.5% increment from 2009) deaths because
of the primary malignant brain and central nervous system tumors in the United States in
2012. It is estimated that 24,620 men and women (13,630 men and 10,990 women) will be
diagnosed and 13,140 (4.26% increment from 2010) men and women are estimated to be
deceased of brain and other nervous system cancer in 2013. Males and females have a 0.7%
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and 0.6% lifetime risk of being diagnosed with a primary malignant brain/central nervous
system tumor. These projections are of major public health interest. However, their inter-
pretation may be complex because of the effect of screening, risk factors and accessibility
of effective treatments.
Crude mortality rates per 100,000 persons based on the 2000 standard US population
were extracted using the SEER*Stat 7.0.5 software of the Surveillance Epidemiology and
End Results program, National Cancer Institute Institutes. We are using 416,480 (229,467
males and 187,013 females) malignant Brain cancer patients, where 381,238 are whites,
24,336 are African Americans and 4,891 others (American Indian/AK Native, Asian/Pacific
Islander, 1969-2007).
The mortality rates were at their highest from 1885 to 1995. After 2000 we observed that
the overall rates are leveling off or declining. From 2003-2008, the median age at death for
cancer of the brain and other nervous system was 64 years of age. Approximately 4.2%
died under age 20; 3.8% between 20 and 34; 7.1% between 35 and 44; 14.9% between 45
and 54; 21.8% between 55 and 64; 22.2% between 65 and 74; 19.6% between 75 and 84;
and 6.3% 85+ years of age. For the first part of our study, we use annual crude mortality
rates in The United states from 1969 to 2007 in 5 year age groups (01-04, 05-09,..80-84,
85+).
Crude rate
Crude incidence/mortaliry rate is the number of new cancers of a specific site/type occur-
ring in a specified population during the year, usually expressed as the number of cancers
per 100,000 per year for the populations at risk. It is calculated using following formula:
Crude rate =
Count
Population
× 100, 000 (4.10)
Age-adjusted rate
An age-adjusted rate is a weighted average of the age-specific (crude) rates, where the
weights are the proportions of persons in the corresponding age groups of a standard pop-
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ulation. The potential confounding effect of age is reduced when comparing age-adjusted
rates using the same standard population. Several sets of standard population data are
included in SEER*Stat. These include the 2000 US standard population as well as stan-
dard millions for the US population (1940, 1950, 1960, 1970, 1980, 1990, and 2000), the
1991 Canadian population, the European population, and the world population (see 2000
US Standard Population vs. Standard Million). The age-adjusted rate for an age group
comprised of the ages x through y is calculated using the following formula:
Age-adjusted rate from x to y =
y∑
i=x
[(
Counti
Popi
)]
× 100, 000×
(
Stdmili∑y
j=x Stdmilj
)
(4.11)
4.3.1 Application of FDA
For this study we obtained the data from the Surveillance, Epidemiology and End Results
(SEER) program of National Cancer Institute in the United States [37]. Specifically, mor-
tality data were obtained from the National Center for Health Statistics (NCHS) available
on the SEER*Stat database. Annual age-specific brain cancer mortality data are designated
by ICD 8 & 9 (1979–1998) code 174 and ICD 10 (1999+) code C50 and are available for
the two racial groups, whites and blacks, and all races combined since 1969 in nineteen
year age-groups : 01-04, 05-09, 10-14, 15-19, 20-24, 25-29, 30-34, 35-39, 40-44, 45–49,
50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84 and 85+.
Figure 7, displays brain cancer mortality rates in US male by age group for the period of
1969-2007. We observe that the mortality rates for ages below 40 years show no obvious
trend, for the same period the pattern of mortality rates for ages more than 40 exhibited sig-
nificant variation of mortality rates for elderly. The graph shows the brain cancer mortality
rates among males between 45-65 years declined slowly throughout the study period. The
pattern for elderly (aged 65 and above) population is clearly increasing from 1969 to 2000
and started declining after 2000. However, mortality rates for the population subgroups
between 45 -65 show slightly decreasing pattern. The mortality rates for the age groups
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80-84 and 85+ are very unstable and difficult to interpret because of the limited availability
of data.
Figure 7.: Age-specific brain cancer mortality by age group among total males (1969-2008). In the figure 49 represents the age group
45-49, 64 represents the age group 60-64 and 89 represent the age group above 85.
In Figure 8, we present the age-specific mortality rates with respect to the year of de-
ceased for the female subpopulation. The trends in mortality rates do not show any visible
pattern for the age-groups less than 40 years. The rates for the age groups 50-54, 55-59,
and 60-64 show decrease in mortality during the whole period of study. Overall, the mor-
tality rates for females is lower than that of female but the age specific mortality rates show
no obvious difference between the rates. Figure 9 displays the age-specific mortality rates
with respect to age for the women sub-population for brain cancer mortality rates during
the entire period of study, 1969- 2008. The graph depicts similar variation of hazard rates
as for the male sub-population. These rates are notably unstable for the young (less than
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Figure 8.: Age-specific brain cancer mortality by age group among total females(1969-2008). In the figure 49 represents the age group
45-49, 64 represents the age group 60-64 and 89 represent the age group above 85.
20 years); monotonically increasing for middle age population (between 20 and 67); and
decreasing with with strong instability for the elderly (67 and above). In general, mor-
tality rates are directly proportional to age, and for every year, highest mortality rates are
observed in the age groups 80- 84, 85 and above, this is true for both male and female
subpopulation.
In Figure 10 we present the mortality rates of the male sub-population for the entire pe-
riod of study. The male brain cancer mortality rates are higher than female in magnitude
but show similar pattern for different clusters of the population. This diagram clearly indi-
cates three different patterns of mortality rates. First, a unstable and decreasing mortality
rates for patients below 20; second, reasonably stable pattern of mortality rates for middle
age population subgroups (ages 20-65) and third, significantly increasing and very erratic
behavior of mortality rates for elderly (ages 65 and above).Three different pattern of mor-
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Figure 9.: Age-specific brain cancer mortality with respect to age for females subgroup of the population (1969-2008).
tality rates by age is present for the whole population and other subgroups of population as
well. However, this behavior of mortality rates is more apparent in male population.
In the next section, we develop smooth functions of mortality rates as a function of age
for different population subgroups. The smooth (or interpolated) functions are developed
for brain and CNS tumor mortality rates, these smooth functions are used to find principal
component to measure the variability of the data. Weighted penalized regression splines
are used to find smooth functional curve with a monotonicity constraint. The curves are
monotonically increasing for age greater than 20, the monotonicity property is violated by
the age groups more than 75. The smoothness of the curves is controlled by an smoothing
parameter λ based on Wood [74]. The term functional refers to the intrinsic structure of the
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Figure 10.: Brain cancer mortality rates as a function of age for male subpopulation (1969-2008).
data under the assumption that there exists a function of x giving rise to the observed data
[26].
4.4 Functional Data Analysis Model
For the given period of study 1969-2008, we assume the existence of the function of age
with respect to the mortality rates. We would like to develop a mathematically independent
set of functions φk which can be approximated by linear combination of K of these func-
tions. The basis system is not specifically defined by the fixed number of parameters but
rather itself is a parameter that we choose as per the nature of the data. One of the primary
criteria to choose basis is to test the behavior of their derivatives, some of the bases that
give reasonable fit may end up with poor derivative estimates. We choose a model with
K = 6 basis functions. The number of basis functions are chosen by minimizing the mean
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square error (MSE ) and mean integrated squared forecasting error (MISFE). The estimated
coefficients are are presented in the bottom of Figure 11.
The functional regression model with six basis function explained 98.8% of the vari-
ability of the data for total observation (both male and female) during the period of study
in the United States. The proportion of variation explained by each basis function in the
decreasing order of their magnitude is 92.0%, 4.8%, 0.6%, 0.6%, 0.6%, 0.3%, and 0.5%
for k = 1, · · · , 6 respectively. The mean square error (MSE) for the variability 0.00082
and the integrated squared error (ISE)is given by 0.07217. For female, the first six basis
functions in the functional model explain 87.6%, 5.5%,1.8%, 1.1%, 0.8%, and 0.7% of the
total variation of female mortality rates with mean squared error 0.00183 and integrated
squared error 0.16050, while 88.6%, 4.8%, 1.7%, 1.2%, 0.7%, and 0.6% of the total vari-
ability of mortality rates are explained for male population with MSE = 0.00153 and
ISE = 0.13532.
The optimal orthogonal basis functions are computed from principal component decom-
position. Figure 11 explores the first six basis function functions together with the corre-
sponding coefficients. The basis functions and the time series coefficients model the overall
variability of the mortality rates. The first basis function (φ1) models the changes in the age
groups less than 20, between 20 and 65, and age groups more than 65; second basis func-
tion (φ2) models the difference between three age groups; (φ3) models variability in the age
group more than 40 years; the fourth basis function explores the variability among middle
aged (20-65) populations; (φ5) and (φ6) are relatively complex to explain and we are not
attempting to explain these function because of their unpredictable variability [76, 77].
The plots of time series coefficients, Figure 11, depicts a continuously increasing pattern
before 1990, while the rates show a declining pattern during the decade of 1990-2000. We
observed that the rates show an increasing pattern in the later years of the study period.
More specifically, the mortality rates are increasing for the age groups more than 65, the
rates are slightly decreasing for the population with the age between 40 and 65, where as
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the rates are leveled off for younger population. The variability of mortality rates for the
patients more than 80 years is remarkably high, which is numerically important and less
explained by the basis functions. The erratic behavior of the death rates may be because of
the measurement error than due to behavior of the rates. Similar study by Coale and Kisker
[78] showed that the mortality data are highly susceptible and fraught with various types
measurement problems. It is more reasonable to have detail and separate study of patients
above 80 years, we excluded the mortality rates for the age groups 80-84 and 85+ in the
later part of our study.
The forecast of the brain cancer mortality rates are calculated by multiplying the time
series coefficients with the basis functions. Figure 12 shows 10-year forecast of mortality
rates for male and female together during the period of study. We observe that the brain and
CNS cancer mortality rates is expected to increase with respect to age. One year and ten
year forecast show a declining pattern of mortality rates for brain and CNS tumor patients
of all the age groups. A significant progress is observed in reducing the mortality rates for
the ages less than 20. However, the declining pattern of mortality rates are inverted for the
elderly.
The difference between the mortality rates is remarkably higher in the age groups more
than 75 years. Average difference of mortality rates in the age groups 75-79, 80-84, 85-89,
and 89+ is 0.05 per 100,000 per year. We observe that the average mortality rates of a
person of 62 years of age is almost 10 times higher than that of a person of 32 years of
age. Long term forecast show that the rates are predicted to decline relatively slowly in
next decade. The mortality rates for the total US population is expected to decrease by
1.58% for the age group of 0-4 years, and at the same time rates are expected to increase by
5.5% for the age group of 80-84. Specifically, the mortality rates are predicted to increase
for all the persons above 65 years of age. For total US population with age less than or
equal to 65 the rates are predicted to decrease linearly at the rate of 0.0145 per 100,0000
per year (p-value <0.05). We also observed that 20th percentile of difference in mortality
rates between 2009 and 2018 is 0.501 per 100,000 pear year; 50th percentile is 0.796; and
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99 percentile of the difference between mortality rates 1.57 per 100,000 per year [7].
Figure 12.: Forecast of age-specific mortality of total brain and central nervous system cancer patients in the United States for 2009 and
2018, with 80% confidence intervals.
In Figure 13, we present one year and ten year prediction intervals for male and fe-
male populations. The mortality rates are expected to increase,(comparing with 2009) for
both the gender by 0.17(0.37%) persons per 100,000 by 2018. For the same period the
mortality rates for males and females separately are expected to increase by 0.33(0.78%)
and 0.11(0.19%) person per 100,000 by 2018. This may be because of erratically higher
mortality rates of elderly population. However,age-specific forecast for 2009 and 2018
show slower rate of decline in female mortality rates in comparison to the male population.
The average increment in mortality rates are 0.33 person per 100,000 and 0.84 person per
100000 for males and females ages below 65 years respectively. We also observed that the
mortality rate for the age groups more than 65 is increasing dramatically, the average rate
of increase in mortality rates for elderly is 1.23 (5%)and 0.44 (0.38%)person per 100000
for males and females respectively (see Table 7). The mortality rates for the elderly popu-
lation is subject to error because of availability of information and erratic behavior in the
mortality rates. Lee and Carter (1991)[67] also mentioned the unreliability of age groups
85+.
In contrast, after dividing the ages into three groups: 0-19 (young adults), 20-64 (middle
age), and 65 and above (elderly). We observe that the mortality rates for younger pop-
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ulation are estimated to decrease with highest declining rate followed by the middle age
population.
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Figure 13.: Forecast of age-specific mortality of brain and central nervous system cancer in the United States for 2009 and 2018 for
male and female subpopulation with 80% confidence intervals.
In Table 7, we present one year and ten year forecast of the mortality rates. The mor-
tality rates for younger subpopulation is significantly decreasing. The average decrease
(from 2009 to 2018) in mortality rates for male and female subpopulation are 1.6 and 1.41
person per 100,000. The variability of the mortality rates for different age groups is clearly
noticeable. Despite the fact that brain and CNS cancer is one of the most vulnerable cancer
for the younger population, the mortality rates are declining faster than middle aged and
elderly population. In a separate study of mortality rates for the age groups 0-19 and 20-64
we report less MSE as well as less ISE in comparison to the models for all the age groups
(See Appendix A and B for forecast of the mortality rates for age groups 0-19 and 20-65).
4.5 Discussion
In this study of brain cancer mortality in the United states, we demonstrate the application
of new forecasting method (Hyndman and Ullah 2007) [28] that models mortality rates
using functional model of age. The mortality-age relationship is modeled by using basis
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Table 7: Forecast and 80% prediction intervals of mortality rates of total US patients of brain and CNS tumors for 2009 and 2018
 
age mean mean mean mean mean mean
2 0.62 0.55 0.70 0.61 0.53 0.70 0.66 0.56 0.79 0.65 0.54 0.78 0.57 0.49 0.66 0.56 0.47 0.67
7 0.88 0.80 0.97 0.87 0.78 0.97 0.87 0.76 0.99 0.85 0.74 0.98 0.88 0.78 1.00 0.88 0.77 1.00
12 0.63 0.56 0.71 0.62 0.55 0.71 0.63 0.55 0.74 0.62 0.53 0.74 0.62 0.53 0.71 0.61 0.52 0.71
17 0.48 0.44 0.53 0.48 0.42 0.54 0.53 0.46 0.61 0.53 0.45 0.62 0.42 0.37 0.49 0.42 0.35 0.49
22 0.53 0.48 0.58 0.52 0.47 0.59 0.62 0.53 0.72 0.60 0.51 0.71 0.42 0.34 0.52 0.42 0.33 0.53
27 0.73 0.66 0.80 0.72 0.64 0.81 0.86 0.75 0.99 0.86 0.73 1.00 0.53 0.45 0.63 0.54 0.43 0.66
32 1.10 1.01 1.20 1.09 0.97 1.22 1.33 1.20 1.47 1.32 1.16 1.50 0.84 0.73 0.98 0.84 0.70 1.00
37 1.63 1.51 1.76 1.62 1.46 1.79 2.00 1.83 2.19 1.99 1.78 2.22 1.24 1.11 1.39 1.23 1.07 1.42
42 2.49 2.33 2.66 2.47 2.27 2.70 3.10 2.84 3.39 3.08 2.78 3.42 1.90 1.71 2.10 1.88 1.66 2.12
47 3.70 3.45 3.97 3.67 3.36 4.01 4.58 4.20 4.99 4.54 4.10 5.03 2.87 2.61 3.15 2.85 2.54 3.18
52 5.48 5.17 5.81 5.45 5.02 5.91 6.73 6.25 7.25 6.69 6.10 7.33 4.29 3.94 4.66 4.26 3.82 4.75
57 8.00 7.62 8.41 7.95 7.40 8.54 9.73 9.13 10.38 9.69 8.93 10.50 6.29 5.84 6.78 6.26 5.67 6.91
62 10.84 10.30 11.41 10.80 10.05 11.60 13.25 12.50 14.06 13.27 12.33 14.27 8.56 7.88 9.30 8.55 7.68 9.53
67 13.88 13.20 14.61 13.91 12.91 14.99 16.83 15.71 18.02 17.01 15.59 18.56 11.13 10.32 12.00 11.17 10.10 12.37
72 17.14 16.05 18.31 17.40 15.70 19.28 20.64 19.15 22.26 21.21 19.11 23.54 14.18 12.93 15.54 14.37 12.62 16.36
77 19.22 17.62 20.96 19.77 17.10 22.86 23.81 21.65 26.19 24.87 21.76 28.42 15.59 13.90 17.48 15.98 13.31 19.19
82 19.94 17.30 22.98 21.05 16.60 26.69 24.69 20.94 29.11 26.64 21.17 33.51 16.66 14.10 19.69 17.35 13.12 22.95
87 17.44 14.63 20.78 18.70 13.89 25.19 23.30 19.00 28.57 25.72 19.24 34.38 14.52 11.82 17.82 15.38 10.89 21.73
80% PI80% PI 80% PI 80% PI 80% PI 80% PI
Total Male Female
2009 2018 2009 2018 2009 2018
expansion of the data which highlights important trend during the period of study. We
studied the patterns of the mortality rates for brain and central nervous cancer in the United
States from 1969-2008. We have shown that the mortality rates will continuously decline
in the future for all brain and CNS patients of age groups 0-19 and 20-64. Higher mortality
rates are estimated for elderly (65 and above) but these rates are heavily influenced by low
sample size and higher fluctuation of mortality rates of the subject age group of the study.
We also observed that male population have homogenous and consistent pattern of mortal-
ity rates than female population. In addition, males have consistently higher mortality rates
than female mortality rates.
We observe a slower rate of decline in mortality in brain cancer in the United States for
next decade. We also report relatively small change in mortality for the age group 20-65,
while the rates are expected to increase for patients more than 65 years of age. Interestingly,
we observed a significant decline in mortality rates for the young population subgroup. Ad-
vancements in treatment have significantly helped to increased survival rates for children
with brain tumors (Legler,1999) [79].
By observing the trend of mortality rates there are at least three age groups with different
pattern of mortality: young adults (0-19) ; middle age (20-64); and elderly (65 and above).
About 75% of children survive at least 5 years after being diagnosed with a brain tumor
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(Neglia JP, Robison LL et al. 2006) [80]. Nevertheless, many childhood brain tumor sur-
vivors are at risk for long-term neurological complications.
The functional form of the data is able to capture the subtle variations in mortality rates,
thus the models and forecasts both have notable strength demographic forecasting [73].
The other studies in modeling mortality and fertility forecasting also have acknowledged
the implication of functional data analysis approach in modeling all causes of mortality
rates (Horiuchi and Wilmoth, 1995) [81] and (Lee and Miller, 2000) [31].
FDA techniques are getting popularity since last decade, especially after the publication
of pioneering book in FDA by Ramsay and Silverman in 2005. This technique has num-
ber of strength in modeling high dimensional and missing data. For a detailed review of
FDA and its application in the different fields of study see (Ullah and Finch 2013) [27].
Functional analysis technique make no parametric assumption about age or period of ef-
fects, variation of mortality rates are presented with respect to time so that for different
ages the fluctuation of rates can be modeled. To the best of our knowledge, no other stud-
ies modeled or forecast the brain cancer mortality rates with age as a functional covariate
over time. This is an alternative to the frequently used annual percentage change (APC)
approach in modeling and forecasting mortality rates. The functional model is free from
the strong parametric assumptions of error and does not assume linear dependency between
the variables age, period, and cohort.
4.6 Contributions
The present study about the crude mortality rates of brain and central nervous system cancer
possess a good contribution to the literature of the population based studies of mortality
rates and their forecast. The highlights of some of the interesting results from Chapter 4
are listed below.
• Our work reconciled the bold theoretical conjecture of FDA about the mortality fore-
casting with the empirical work using the brain cancer mortality rates of the Unites
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States, 1969-2008.
• The mortality rates for the population ages 0-20 estimated estimated to decrease sig-
nificantly while the rates for elderly (ages more than 65) is predicted to increase and
mortality rates are leveled off for the middle age (20-65) population.
• A novel approach in long-term mortality forecasting showed significant improvement
in childhood mortality rates.
• The statistical prediction intervals of the mortality forecast are presented for different
subgroups of the population by incorporating all sources of variation are the most ac-
curate to the data.
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Chapter 5
Regional Comparisons of Brain Cancer Mortality Rates for Contract
Health Service Delivery Areas
5.1 Introduction
The term Contract Health Services originated under Bureau of Indian Affairs (BIA) when
medical health care services were contracted out to health care providers. In 1955 the
Transfer Act moved health care from BIA to the Department of Health Education and
welfare and established the Indian Health Services (IHS). The journal of United States
government “FEDERAL REGISTER” published a notice under the authority of 43 FR
34654in August 4, 1978. The geographic boundaries of contract health service delivery
area (CHSDA) was redesigned, the proposed CHSDA be comprised of seven counties in
the States of South Dakota and Nebraska, Bennett, SD, Cherry, NE, Mellette, SD, Todd,
SD, Tripp, SD, Gregory, SD and Lyman, SD. On August 4, 1978, the IHS published reg-
ulations establishing eligibility criteria for receipt of contract health services, and for the
designation of CHSDAs (43 FR 34654, codified at 42 CFR 136.22, last published in the
2002 version of the Code of Federal Regulations) (see http:www.ihs.gov).
IHS have to compete with other federal agencies for the funding of the program through
congress. According to federal health program for American Indian and Alaskan Natives,
contract health service is not fully funded, it is designated as the payor of the last resort,
that is all other available alternate resources including IHS facilities must first be used be-
fore payment is expected.
An identified member of Indian community is facilitated with health service at the ex-
pense of IHS in the designated area. When producing statistics using SEER Incidence data
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for American Indians/Alaska Natives, SEER includes cases that are in a CHSDA. We have
used CHSDA 2006 definition through SEER*stat to extract the information about patients
in this particular group. We calculated the mortality rates using SEER*Stat for 639/3141
counties in the United States where IHS provides the hospital facilities through public, pri-
vate and other hospitals in the expense of IHS.
We aim to compare the age-adjusted brain cancer mortality rates of white race with
four different regions where IHS provides hospital facilities. Officially, there are seven
geographical regions where IHS provides health service facilities through the support of
the United States Government. We could not include three regions: Alaska, Southeast and
evacuees of Katrina and Rita because of the insufficient and heavily missing observations.
Our study considers the American Indian population of the four major geographic regions
together with the white population of the United States. The major geographic regions are
listed below:
• Pacific Coast: California, Oregon, Washington
• Southern region: North Carolina,Florida, Georgia, Texas, Mississippi
• Northern region: Connecticut, Main, New Hampshire, Rhode Island, Vermont, New
Jersey, New York
• East: East of Mississippi river and is divided by Ohio river and Appalachian mountain
In this study we attempt to explore the information on rate function in longitudinal
studies by examining data provided by the Surveillance, Epidemiology, and End Results
(SEER) Program. Population-based data from the SEER Program are used to calculate the
incidence, mortality and survival rates for people with brain cancer. We use annual age-
adjusted brain cancer mortality rates from 1969 to 2009 in 5-year age groups (0-04, 5-09,
10-14,15-19, 20-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74,
75-79, 80-84, 85+) for Contract Health Service Delivery Areas (CHSDA) and compare the
epidemiological effect with respect to the respective demographics.
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Age-specific mortality curves were obtained using nonparametric smoothing methods.
We apply functional time series models on age-specific brain cancer mortality rates for
each group of patients, and forecast their mortality curves using exponential smoothing
state-space models.
We developed a functional linear model (Ramsay and Silverman, 2005)[26] to model the
annual brain cancer mortality data. One and ten year prediction intervals are also estimated
to find the trends of the mortality rates in four major geographic regions and compared the
long term and short forecast with white population of the United States.
5.1.1 Materials and Methods
Time trends in age-adjusted mortality rates of brain and central nervous system cancer
are described in population based cancer registries aggregated with state, total U.S.(1969-
2009). Data on mortality from SEER program of NCI is considered in the CHSDA regions:
Alaska, East, Northern Plains, Southern Plains, Pacific Coast, Southwest, Unknown - Kat-
rina/Rita Evacuees - Populations Only - 2005. However, we only considered East, Northern
plains, and pacific coast in our analysis because of the large number of missing/insuffficient
data in the remaining regions. Higher mortality rates of white race has been reported in the
literature. We compare mortality rates of whites with population of Indian descent belong-
ing to Indian community with in the U.S. on reservation located CHSDA. The selected
patients from CHSDA can be from Indian tribe, or person with a close economic and social
ties with the Indian tribe.
The age distribution of the selected population subgroups differs substantially from the
overall American population because in the Indian community there are relatively less num-
ber of people who are more than 65 years. The small number of younger (less than 20 years)
and elderly (more than 65 years) may generate statistically unstable results (Kangmin Zhu
2009, Lee-Carter 1991) [67].
After 2004 November SEER age-adjusted rates are calculated using the 2000 US stan-
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dard population based on single years of age. National cancer institutes SEER*Stat version
8.0.1 is used to extract the age-adjusted mortality rates. Age-adjusted mortality rates are
considered to be reasonable for comparison if the rates are calculated for different pop-
ulation subgroups. In this chapter, our primary goal is to compare the mortality rates of
American Indians in CHSDA with that white race in the United States.
Logarithm of mortality rates are modeled using Hyndman and Ullah (2007) [28] ap-
proach in the realm of functional data analysis (Ramsay and Silverman 2005) [26]. Lee
Carter (1992) [67] used random walk with drift model to forecast mortality rates and ex-
trapolation of the data is made using ARIMA time series model models (Makridakis et
al.1998) [82].
The coefficients ax and kt in the equation (4.1) are calculate using singular value de-
composition (Trefethen and Bau, 1997) [83] method. The Hyndman and Ullah approach
assumes mortality as a smooth function of age and smoothness is performed through non-
parametric smoothing methods. We used function principal component analysis to find the
basis function as a measure od variability of data which is a significant improvement over
LC-method with only one component of (kt, bx). We use a more general time series ap-
proach to find the forecasting coefficients; primarily ARIMA models are used to develop
robust estimates which can model the unusual years due to war or epidemics.
The mortality rates mt are assumed to be binomially distributed with weights as an in-
verse of variance (Hyndman and Ullah, 2007) and use weighted penalized regression spline
(Wood,2003; He and Ng 1999)[84, 85]. In this study we used B-spline, and penalized re-
gression splines whenever monotonicity is satisfied. In other cases, interpolation is made to
develop rates as a function of age. Principal component analysis is used to find orthonormal
basis functions. For a fixed number of basis function K, we minimize the mean integrated
squared error(4.5) to find orthonormal basis function by using the function of annual log
mortality rates with respect to their age.
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Two step robust principal component method yields (3.9), the coefficients βt,k for k =
1 · · ·K and t = n+1, · · ·n+h can be obtained using univariate time series ARIMA model.
The orthonormality of basis functions implies the coefficients βt,k and βt,l are uncorrelated
for k 6= l. In addition, various types of outliers are are modeled in the fitted ARIMA (Chen
and Liu 1993) in such a way that the outlying values do not affect the forecast.
Equation (4.6) is used to calculate h-step forecast of βn+h,k using the estimated time se-
ries βˆ1,k · · · βˆn,k. The variance of the forecast coefficients is obtained from time series mode
and that of estimate µˆ(x) can be obtained from the smoothing function. The prediction in-
tervals of forecast are calculated assuming the normality of errors (Hyndman and Ullah,
2007) while bootstrap method can be used to find the prediction interval if the normality of
error is not justified.
5.2 Regional Comparisons of Mortality Rates
We use functional data analysis techniques and principal component decomposition method
to find basis functions to develop forecasting model for Indian population residing in East,
Northern plains, Pacific coast and white population of the United States. The age-adjusted
mortality rates are comparable for different regions and age-groups as they are standardized
using 2000 US standard population. A Set of basis functions K is selected by minimizing
the mean squares error(MSE), mean integrated squared error (MISE)and mean integrated
sum of forecasting error(MISFE).
5.2.1 Results
For the Indian population in East region a model with K = 6 basis functions are selected
capturing 97% of the variation. The proportion of variation explained by each basis func-
tion is 79.7%, 10.2%, 2.2%, 1.9%, 1.7%, 1.3% for k = 1, · · · , 6 respectively. The MSE
and ISE for the selected model are observed to be 00133 and 0.1091. In the same model
a tuning parameter λ = 4 is used to control the degree of robustness. Ten-year forecasts
are corresponding prediction interval based on ARIMA time series models are developed
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to analyze the trends of brain cancer mortality.
For the Northern Plains, six basis functions are selected explaining 93.6% of the varia-
tion of the data with individual proportion of variations 69.9%, 10.5%, 4.3%, 3.7%, 3.1%,
2.1% for the first six basis functions. The mean square error and mean integrated squared
error are reported to be 0.00345 and 0.2893 respectively.
For the Pacific Coasts, the first six basis functions explained a total of 93.8% of the vari-
ation. Six basis functions separately explain 59.7%, 7.6%, 7.0%, 6.4%, 4.7%, 3.9%, 2.5%,
and 2.0% of the total variation of the mortality rates with MSE of 0.00267 and and ISE of
0.22474.
The mortality rates for the white race modeled with K = 6 basis functions. The ro-
bustness parameter was set to λ = 4 and minimum number of observations used in fitting
model was n = 20. The fitted basis function φˆk, k = 1, · · · 6 and associated basis functions
βˆt,k are selected on the basis of minimum MSE(0.0083), and ISE (0.0693). The basis func-
tions explain a total of 97.7% of variation of rates around the mean log mortality curve.
The proportion of variation explained by each basis function is 85.6%, 7.4%, 1.6%, 1.4%,
1.0%, and 0.7% respectively.
5.2.2 Comparison of Regional Mortality Rates
Forecast of average mortality rates and 80% prediction intervals of annual age-adjusted
brain cancer mortality rates of Indians in Northern Plains, Eastern regions, pacific coast
and whites races are shown in Table 8 and Table 9. We observe that brain cancer mortality
rates in the Northern Plains are higher than that of East while the comparisons of rates
between Pacific and East regions show no significant difference between the rates. We
computed one year and ten years estimates of future mortality rates using ARIMA model.
The parameters of the model were selected by minimizing MSE. We observe that the age-
specific mortality rates of all the people (< 65 years) of Indian origin who residing in East
and Pacific Coast together with white(< 65 years) population are expected to decline. For
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the same geographic regions and races the brain cancer mortality rates are estimated to in-
crease for elderly (> 65 years) population.
In contrast, for the Northern regions the mortality rates are predicted to increase for the
middle aged population (20-65 years) and decrease in mortality rates is observed for young
(< 20) and elderly (> 65).
Table 8: Forecast and 80% prediction interval of mortality rates for total patients of brain and CNS tumors in 2010 and 2019 for North
and East regions
We compared the predicted mortality rates of Indian Americans of three different regions
with the mortality rates of white in the United States. Tables 8 and 9 show the mortality
rates for Eastern and pacific regions are estimated to be lower than that of whites while this
relation is inverted when comparing with Northern plains. In general, white race is consid-
ered to have higher incidence and mortality rates of cancer, higher brain cancer mortality
rates of Indian American is a striking result of predicted rates and warning signal for the
authorities and Indian community residing in Connecticut, Main, New Hampshire, Rhode
Island, Vermont, New Jersey and New York.
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Table 9: Forecast and 80% prediction interval of mortality rates for total patients of brain and CNS tumors in 2010 and 2019 for patients
with Indian origin of Pacific Coasts compared with white population of the United States
In Figure 14 we report one year and ten years predicted intervals for American Indians in
East, Northern Plain, Pacific Coast and whites population in the United States. The predic-
tion intervals for the elderly population is relatively wider than the rest of the age groups.
Results from this study are another addition to the literature that there exists regional effects
in brain cancer mortality. The rainbow color line in the prediction intervals are estimated
values for the years 2011-2019. We plot only the estimate rates and compare the regional
estimates with white race in Figure 15.
62
0 20 40 60 80
−
1
0
1
2
3
4
white
Age
Lo
g 
de
at
h 
ra
te
2010
2019
0 20 40 60 80
−
1
0
1
2
3
4
AI:East
Age
Lo
g 
de
at
h 
ra
te
2010
2019
0 20 40 60 80
−
1
0
1
2
3
4
AI:Northern plains
Age
Lo
g 
de
at
h 
ra
te
2010
2019
0 20 40 60 80
−
1
0
1
2
3
4
AI:Pacific coast
Age
Lo
g 
de
at
h 
ra
te
2010
2019
Figure 14.: Forecast of age-specific mortality rates of brain and central nervous system cancer of American Indian population in east,
northern plains, pacific regions and whites in the United States for 2010 and 2019 including 80% confidence intervals.
Figure 15 contrast the estimated age-adjusted annual mortality rates from 2010 to 2019
for American Indians residing three major geographical regions of cancer registry and white
race over age. Only the young (< 20) and elderly (> 65) are predicted to experience signif-
icant changes in mortality rates over the study and predicted period. The American Indians
in Northern plains are estimated to possess significant higher mortality rates followed by
white races American Indians in the Pacific Coasts. The CHSDA service receivers in the
east regions show the lowest mortality rates among the study group considered for our anal-
ysis. Thus, it is reasonable to assume regional effects on the brain cancer mortality rates,
and the notion of American Indians have lower mortality rates is not supported by our
analysis. Our model rather showing the higher brain cancer mortality rates for American
Indians in some of the major cancer registries than white race.
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Figure 15.: Regional Comparisons and forecast of average age-adjusted mortality rates of brain and central nervous cancer in the United
States for American Indian population in east, northern plains, pacific regions and whites (2010 and 2019).
5.3 Discussion
In contrast to the earlier reports of higher mortality rates for white population, this popula-
tion based study found that American Indians who are habitat of some of the regions in the
United States have even higher mortality rates than whites. To provide a more comprehen-
sive study of the brain cancer mortality rates we analyzed the mortality patterns covering
large geographic area of US over longest period of the available data. In addition, we have
used newly developed statistical methods (Ramsay and Silverman 2005; Hyndman and Ul-
lah 2007) to examine the mortality trends in the most recent time in which the data was
available.
The mortality rates are leveling off or declining for young and middle age population,
whereas increasing for the elderly. For the American Indians in the East and Pacific Coast
regions the mortality rates level or declined in all but elderly (≥ 65years). Similarly white
race also depict steadily declining pattern of mortality for all the population subgroup ex-
cept elderly (Pokhrel, 2012) [86]. However, the American Indians in the Northern plains
show increasing pattern of mortality rates for the ages between 15 to 65. For the same
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tribe, the mortality rates are sharply declining for the elderly and modestly declining for
the younger population. The contrasting pattern of mortality rates among American Indi-
ans is a matter of further study.
As per our knowledge there is no comprehensive study about the brain cancer mortality
rates focusing primarily on CHSDA people. The comparisons of the brain cancer mortality
rates of the American Indians with white population has reveled further distinction of mor-
tality rates by races.
In contrast to the existing literature that the people from Indian origin are likely to have
lower cancer mortality [87, 88], we observed that in some regions of the United States the
brain cancer mortality rates for American Indians rates are even higher than that of white
race. For the East region, brain cancer mortality rates are predicted to be steadily higher
for one year and ten years predictions after the study period of the data.
In Northern plains, American Indians are predicted to have higher mortality rates for all
the age groups except 15-19, 70-74, and 75-79. In the pacific Coasts, the American Indians
show higher mortality rates for elderly with no specific pattern of mortality rates while
the rates are leveled off for the age group 20-24 and for the same period of study white
subpopulation is predicted to have higher mortality rates for the rest of the age groups.
5.4 Contributions
The demographic, racial, gender and most importantly regional effects are core part of epi-
demiological studies. In this chapter we deployed age-adjusted brain cancer mortality rates
to reveal the differences between mortality rates. We have found mortality rates between
Indian Americans and white Americans population to be significantly different.
• A notable regional differences in mortality rates were observed.
• American Indians in the Northern plains are estimated to have significantly higher mor-
tality rates than that of the white race.
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• The American Indian population in the Northern plain of the US shows an increasing
pattern of mortality rates for the forecast period as well as the the periods we investi-
gated.
• The mortality rates of elderly population are expected to increase for CHSDA as well.
• A clear indication of regional effects demands a necessity of further research and re-
quires essential measures to investigate the etiology of the disease.
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Chapter 6
Summary and Future Work
6.1 The End of the Beginning
This dissertation is divided into two distinct but strongly connected sections, first dealing
with the brain tumor sizes and their distributions in demographic and histological sub-
groups (chpaters 2 and 3), and second dealing with brain cancer mortality rates to depict
gender, racial, and regional effects (chapters 4 and 5). The aim of the study has been to
develop a comprehensive inferences about the brain tumor sizes as well as about the mor-
tality rates; number of interesting results are found.
The development of quantile regression models (Koenker and Hallock 2001) [9] and
functional data analysis (Ramsay and Silverman, 2005) [26] techniques lead us to explore
these new techniques in the epidemiological studies of brain and central nervous system
data. In chapters 2 and 3 we discussed about the probability density function of the tumor
sizes. The heavy tailed distributions: “Dagum” and “Weibull” distribution were observed
to be fitted to male and female population subgroups. Tumor sizes at both end of the fitted
distributions are of matter of their own right. Quantile regression models reveled the effects
of larger and smaller tumor sizes on age, race and gender. This is a clear extension in the
literature of brain tumor sizes and their epidemiological measures.
Mortality rates are a matter of significant importance in planning and policy making.
In chapters 4 and 5, the brain cancer mortality rates are discussed in gender, racial, and
regional level. The improvements of in childhood mortality rates, increasing mortality rates
for elderly, and largely stationary mortality rates in middle aged population have clearly
signaled the effect of age in cancer. The increasing mortality rates for the elderly could an
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alarming signal in health care, public health and insurance industry. The report on Contract
Health Service Delivery Areas (CHSDA) is intended in understanding how mortality rates
are influenced by racial and regional effects. The results of chapter 5 clearly indicate that
all the American Indians do not have lower mortality rates than white populations; in some
cases they have even higher mortality rates than whites.
6.2 Probability Density Functions and Quantile Regression
Probability density function (pdf) is a major tool to guide the statistical analyst about the
direction of statistical inferences. In chapter 2 we developed pdfs of the brain tumor sizes
for demographic and gender subgroups of the population in our study. The understanding
of pdfs’ could lead us to disclose the underlying properties of the data including mean,
median, mode, skewness, kurtosis, standard deviation, and coefficient of variation. De-
scriptive statistic is a small but igniting features of data that play a role of positive catalyst
in model building procedure. The highly skewed behavior of the brain tumor sizes lead us
to model these data beyond ordinary linear regression.
In order to explore the effects of covariates on brain tumor sizes a good understanding
of the extreme observations on response variable is critical. This was the aim of chapter
3. A brief explanation of applicability of quantile regression model in the subject of our
interest was discussed in section 3.2.1 followed by the quantile regression models in 3.2.2.
The difference between the effects of covariates on the lower and upper end of the quantiles
of the tumor sizes was explained by the model. One of the major findings of this work is
the interaction of race, gender, age on on different quantiles of brain tumor sizes. We also
observed a significant difference between male and female brain tumor sizes, the largest
difference between the quantiles of the brain tumor sizes for males and females is 9.93mm
at the 95% quantile (95% CI is between 3.39 and 16.47).
68
6.3 Mortality rates and FDA
In chapter 4 we report functional linear model and forecast brain cancer mortality rates
to observe the current and future trends of mortality rates. The work on mortality rates
was primarily divided into two sections based on rate of change of mortality rates with
respect to age. First part of the analysis describes the mortality rates for all the age groups
whereas the second part investigates the functional model by clustering data into three age
groups: young (< 20 yeras), middle age (20 − 65 years), and elderly (> 65 years). The
mortality rates are continuously declining for overall papulation for our study period. It
was particularly encouraging to observe declining mortality rates especially among young
subgroup of the population (brain tumor is among the most vulnerable cancer among chil-
dren). Only the youngest and oldest groups of population experienced significant changes
in mortality rates during the study period (1969 through 2008), the decreasing pattern of
mortality is more visible after the period of late 80s. The decline in mortality rates are par-
tially ascertained to the introduction of magnetic resonance imaging (MRI) in mid-1980s
and computed tomography (CT) (Legler et al. 1999)[79].
The second interesting result arose from the work after subdividing the data into three
clusters of age. In a separate analysis of the data for young population, we estimated and
forecast lower mortality rates than studying all the age groups together. The prediction
intervals are narrower in most of the age groups after clustering the data into three popu-
lation subgroups. The mortality rates are significantly lower in females than in males, this
relation continues in the separate study of younger and middle age population subgroups.
In addition, the predicted average mortality rate for both one and ten years are estimated
to be lower in the data after clustering than before clustering. Mortality rates for young
and middle age subgroups of the population are predicted to decrease in the clustered data
while the rate of decrement is lower in the clustered data than in the complete data.
We also tested the FDA procedure by fitting the earlier portion of the data and forecast-
ing the the data which was not used for modeling. The forecast is right on the target with
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estimated value within the prediction band. Our results are limited to specific cancer, fore-
casting period, gender and adopted races, it is likely that they may be widely generalized
to other cancers, geographic areas and demographic subgroups of the population.
6.3.1 CHSDA
Age-adjusted brain cancer mortality of American Indians in East, Northern plains, and Pa-
cific coasts are compared with the the mortality rates of whites in chapter 5. The purpose of
this particular research was to present the rate of change of brain cancer mortality rates in
different geographic regions where medical facilities are provided with a considerable help
of IHS. The study of age-specific mortality rates brought some interesting comparisons and
added some new results in the literature of demographic forecasting.
The common belief that the mortality rates of American Indian is less than that of white
was found to be reversed for patients less than 65 years in Northern plains and more than 65
years in Pacific Coast. We observed regional effects on mortality rates in Figure 15 where
we observed higher mortality rates of American Indians than that of white race. Among
the American Indian mortality rates; highest overall mortality rates were observed in North,
followed by East and Pacific coasts respectively. We are thus wary of health policies of nar-
row scope and put “all the resources in one basket” and focus on just one race or one area.
Instead, our result favor broad-based health policies that offer support to different demo-
graphics subgroups and geographic areas to entertain the resources in the basis of current
issues not by traditional beliefs.
The overall mortality rates for American Indians in Northern plains is estimated to in-
crease for age group 20-65 while slower decrease was estimated for age group 2-15, and
significantly higher mortality rates were predicted for elderly. On the other hand, the fore-
cast for East and Pacific Coasts show slight decrease in mortality rates till 2018 for the age
group 0-65 with significant increase in elderly population. However, for the white popula-
tion, slowest decrease in mortality rates for the age group of 0-65 was predicted among the
groups of the population under our study while for whites, increase in mortality rates was
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observed for the age group 65-85.
6.4 Future Work
In statistics, data are used to estimate functions; the classical examples of function are
density functions, regression functions, hazard functions, link functions, learning curves,
growth curves, longitudinal models, time series etc. We would like to capture the important
feature of data together with the amount of functional variations by merging the concept of
variance decomposition and linear modeling. Differential equation could be a strong tool
to integrate such type of functions solely by the data. We are working to develop a set of
differential equations to characterize the rate of change of incidence, mortality and survival
using method of principal differential analysis (Ramsay et.al. Journal of Royal Statistical
Society, 1995, 58 No 3, pp 495-508).
In the present study, year of death (calender period) is considered to extract the morality
rates from SEER*stat. Calender period mortality trends can disclose the effects of new
medical inventions and public health policy intervention but it fails to incorporate the year
of birth (cohort) effects. Later type of effects can reflect the risk factors associated with the
rates. We would like to develop models and forecast the mortality rates by incorporating
the changes in risk factors like treatments, screening, hormone therapy and exposure to
hazardous chemicals and more.
We used splines by fixing the knot location in advance, and optimization is made by
multiplying the coefficients with the spline basis functions derived from ideas of fixed knot
sequence. Researchers have also made a significant contribution in developing free-knot
splines, for recent work in free-knot spline see (Lindstorm, 2002)[89], (Mao and Zhao,
2003) [90], (Gervini, 2006)[91], (Sangalli, 2009) [92]. Free-knot spline procedure can be
computationally severe but natural for the data with strong curvature, specially in the re-
gions which are previously unknown.
One of the most important development in statistics in recent years has been the develop-
71
ment of Quantile Regression(Ramsay and Silverman 2005, p. 79-80)[26]. The application
of quantile regression to spline smoothing problem can be a strong bridge to connect two
great concepts in modeling and forecasting: quantile regression and functional data analy-
sis. We would like to extend our work in modeling mortality rates using different smooth-
ing techniques including knot-free method to model the data; especially in the regions with
sparse data, for example near the boundaries. We believe that this new technique will be
helpful to model the mortality and incidence rates of elderly, which are not sufficiently
captured by the existing literature in population based mortality forecasting methods.
We aim to develop a comprehensive monograph about the epidemiology of brain tumor,
effects of tumor registry, gender, histology and age are studied in [93, 94] where as relative
survival of brain tumor cases is studied in [50].
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Appendix A
Quantile Regression Coefficients
Table 10: Ordinary and Quantile regression estimates of the equation (3.9): the coeffi-
cients on “tumor sizes” are reported for 19 quantiles and the mean. Coefficients significant
at the 5% level appear in bold.
Intercept Race 1 Race 2 Sex 1 Age Age*Sex1 Age*Race1 Age*Race2 Sex1*Race1 Sex1*Race2
OLS 41.027 0.013 -0.545 1.356 -0.054 0.054 -0.003 -0.050 -0.447 2.369
Quantile Regression
5 13.352 -3.352 -3.352 1.941 -0.058 -0.000 0.058 0.058 0.058 -1.941
10 17.686 -1.801 -1.758 2.475 -0.086 0.032 0.054 0.020 -0.360 -0.235
15 21.216 -0.489 -2.640 0.783 -0.093 0.060 0.033 0.033 -1.510 0.640
20 24.200 -4.200 -1.765 4.400 -0.100 0.000 0.100 0.013 0.600 1.339
25 28.500 -1.258 -1.351 1.816 -0.125 0.080 0.044 -0.004 0.942 1.034
30 29.257 1.219 0.084 1.092 -0.085 0.079 0.006 0.036 -1.568 1.227
35 32.454 -0.608 -0.560 2.874 -0.091 0.051 0.039 -0.037 -1.720 0.767
40 32.83 0.298 0.876 4.164 -0.044 0.044 0.000 -0.071 -1.298 0.338
45 38.843 -0.093 -1.266 1.156 -0.093 0.093 0.000 -0.038 0.093 1.574
50 40.208 0.347 -1.689 -0.208 -0.069 0.069 -0.000 -0.037 -0.347 3.800
55 40.000 0.000 0.857 1.686 -0.000 0.019 -0.000 -0.107 0.254 4.069
60 43.058 0.150 1.032 2.141 -0.035 0.071 -0.006 -0.078 -0.409 1.579
65 49.073 -0.341 -3.489 0.926 -0.073 0.073 -0.000 -0.001 0.341 3.913
70 50.142 0.311 -2.169 -0.192 -0.017 0.030 -0.012 -0.049 -0.261 4.775
75 50.000 0.000 0.746 5.000 -0.000 0.000 -0.000 -0.029 -2.000 -0.328
80 58.106 -2.160 -3.224 0.968 0.053 0.067 -0.014 -0.029 3.085 4.164
85 60.000 0.968 -2.652 -0.187 0.000 0.031 -0.031 0.087 -0.781 6.126
90 68.000 -1.615 -7.014 0.768 0.000 0.019 -0.076 -0.019 2.905 8.246
95 70.000 -0.071 3.142 9.928 0.035 -0.035 -0.035 -0.107 -3.607 0.928
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Appendix B
Basis Functions and Prediction Intervals
Table 11: Forecast and 80% prediction interval of mortality rates for young adults(0-19)in 2009 and 2018
85
Table 12: Forecast and 80% prediction interval of mortality rates for the age group of 20-64 years in 2009 and 2018
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